AU2017202081A1 - L-ornithine phenyl acetate and methods of making thereof - Google Patents

Abstract

L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING Disclosed herein are crystalline forms of L-ornithine phenyl acetate and methods of making the same. The crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

Description

L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF

CROSS-REFERENCE TO RELATED APPLICATIONS 100011 This application claims the benefit of priority of U.S. Provisional Application No. 61/166,676, filed April 3, 2009, The priority document is hereby incorporated by reference in its entirety. The present application is a divisional of AU 2015221466, the entire specification of which is incorporated herein by cross-reference.

BACKGROUND

Field [0002] The present application relates to the fields of pharmaceutical chemistry, biochemistry, and medicine. In particular, it relates to L-ornithine phenyl acetate salts and methods of making and using the same.

Description [0003] Hyperammonemia is a hallmark of liver disease and is characterized by an excess of ammonia in the bloodstream. Hepatic encephalopathy is a primary clinical consequence of progressive hyperammonemia and is a complex neuropsychiatric syndrome, which may complicate acute or chronic hepatic failure. It is characterized by changes in mental state including a wide range of neuropsychiatric symptoms ranging from minor signs of altered brain function to overt psychiatric and/or neurological symptoms, or even deep coma. The accumulation of unmetabolized ammonia has been considered as the main factor involved in the pathogenesis of hepatic encephalopathy, but additional mechanisms may be associated.

[0004] L-Omithine monohydrochloride and other L-omithine salts are available for their use in the treatment of hyperammonemia and hepatic encephalopathy. For example, U.S. Publication No, 2008/0119554, which is hereby incorporated by reference in its entirety, describes compositions of L-ornithine and phenyl acetate for the treatment of hepatic encephalopathy, L-ornithine has been prepared by enzymatic conversion methods. For example, U.S, Patent Nos. 5,405,761 and 5,591,613, both of which are hereby incorporated by reference in their entirety, describe enzymatic conversion of arginine to form L-ornithine salts. Sodium phenyl acetate is commercially available, and also available as an injectable solution for the treatment of acute hyperammonemia. The injectable solution is marketed as AMMONUL.

[0005] Although salt forms may exhibit improved degradation properties, certain salts, particularly sodium or chloride salts, may be undesirable when treating patients having diseases associated with the liver disease, such as hepatic encephalopathy. For example, a high sodium intake may be dangerous for cirrhotic patients prone to ascites, fluid overload and electrolyte imbalances. Similarly, certain salts are difficult to administer intravenously because of an increased osmotic pressure, i.e., the solution is hypertonic. High concentrations of excess salt may require diluting large volumes of solution for intravenous administration which, in turn, leads to excessive fluid overload. Accordingly, there exists a need for the preparation of L-omithine and phenyl acetate salts which are favorable for the treatment of hepatic encephalopathy or other conditions where fluid overload and electrolyte imbalance are prevalent.

SUMMARY

[0006] Some embodiments disclosed herein include a composition comprising a crystalline form of L-omithine phenyl acetate.

[0007] In some embodiments, the crystalline form exhibits an X-ray powder diffraction pattern comprising at least one characteristic peak, wherein said characteristic peak is selected from the group consisting of approximately 6.0°, 13.9°, 14.8°, 17.1°, 17.8° and 24.1° 2Θ. In some embodiments, the crystalline form exhibits an X-ray powder diffraction pattern comprising at least three characteristic peaks, wherein said characteristic peaks are selected from the group consisting of approximately 6.0°, 13.9°, 14.8°, 17.1°, 17.8° and 24.1° 2Θ. In some embodiments, the crystalline form exhibits an X-ray powder diffraction pattern comprising characteristic peaks at approximately 6.0°, 13.9°, 14.8°, 17.1°, 17.8° and 24.1° 2Θ.

[0008] In some embodiments, the crystalline form has a melting point of about 202° C. In some embodiments, the crystalline form exhibits a single crystal X-ray crystallographic analysis with crystal parameters approximately equal to the following: unit cell dimensions: a=6.594(2) A, b=6.5448(18) A, c=31.632(8) A, α=90°, β=91.12(3)°, γ=90°; Crystal System: Monoclinic; and Space Group: P2]. In some embodiments, the crystalline form is represented by the formula [C5H13N2O2HC8H7O2].

[0009] Some embodiments have the crystalline form exhibit an X-ray powder diffraction pattern comprising at least one characteristic peak, wherein said characteristic peak is selected from the group consisting of approximately 4.9°, 13.2°, 17.4°, 20.8° and 24.4° 2Θ. In some embodiments, the crystalline form exhibits an X-ray powder diffraction pattern comprising at least three characteristic peaks, wherein said characteristic peaks are selected from the group consisting of approximately 4.9°, 13.2°, 17.4°, 20.8° and 24.4° 2Θ. In some embodiments, the crystalline form exhibits an X-ray powder diffraction pattern comprising characteristic peaks at approximately 4.9°, 13.2°, 17.4°, 20.8° and 24.4° 2Θ.

[0010] Some embodiments have the crystalline form comprising water and/or ethanol molecules. In some embodiments, the crystalline form comprises about 11% by weight of said molecules as determined by thermogravimetric analysis. In some embodiments, the crystalline form is characterized by differential scanning calorimetry as comprising an endotherm at about 35° C. In some embodiments, the crystalline has a melting point at about 203° C.

[0011] Some embodiments have the crystalline form exhibiting a single crystal X-ray crystallographic analysis with crystal parameters approximately equal to the following: unit cell dimensions: a=5.3652(4) A, b=7.7136(6) A, ¢=20.9602(18) A, a=90°, β=94.986(6)°, γ=90°; Cr ystal System: Monoclinic; a nd S pace Group: P2\. In some embodiments, the crystalline form is represented by the formula [C5H13N202][C8H702]Et0H.H20.

[0012] Some embodiments have the crystalline form exhibiting an X-ray powder diffraction pattern comprising at least one characteristic peak, wherein said characteristic peak is selected from the group consisting of approximately 5.8°, 14.1°, 18.6°, 19.4°, 22.3° and 24.8° 2Θ. In some embodiments, the crystalline form exhibits an X-ray powder diffraction pattern comprising at least three characteristic peaks, wherein said characteristic peaks are selected from the group consisting of approximately 5.8°, 14.1°, 18.6°, 19.4°, 22.3° and 24.8° 2Θ. In some embodiments, the crystalline form exhibits an X-ray powder diffraction pattern comprising characteristic peaks at approximately 5.8°, 14.1°, 18.6°, 19.4°, 22.3° and 24.8° 2Θ.

[0013] In some embodiments, the crystalline form is characterized by differential scanning calorimetry as comprising an endotherm at about 40° C. In some embodiments, the crystalline form comprises a melting point at about 203° C.

[0014] In some embodiments, the crystalline form exhibits an X-ray powder diffraction pattern comprising at least one characteristic peak, wherein said characteristic peak is selected from the group consisting of approximately 13.7°, 17.4°, 19.8°, 20.6° and 23.7° 2Θ. In some embodiments, the crystalline form exhibits an X-ray powder diffraction pattern comprising at least three characteristic peaks, wherein said characteristic peak is selected from the group consisting of approximately 13.7°, 17.4°, 19.8°, 20.6° and 23.7° 2Θ. In some embodiments, the crystalline form exhibits an X-ray powder diffraction pattern comprising characteristic peaks at approximately 13.7°, 17.4°, 19.8°, 20.6° and 23.7° 2Θ.

[0015] In some embodiments, the crystalline form is characterized by differential scanning calorimetry as comprising an endotherm at about 174° C. In some embodiments, the crystalline form has a melting point of about 196° C. In some embodiments, the crystalline form comprises a pharmaceutically acceptable carrier.

[0016] Some embodiments disclosed herein have a composition comprising: at least about 50% by weight of a crystalline form of L-ornithine phenyl acetate salt and at least about 0.01% by weight benzoic acid or a salt thereof.

[0017] In some embodiments, the composition comprises at least about 0.10% by weight benzoic acid or a salt thereof. In some embodiments, the composition comprises no more than 5% by weight benzoic acid or a salt thereof. In some embodiments, the composition comprises no more than 1% by weight benzoic acid or a salt thereof.

[0018] In some embodiments, the composition further comprises at least 10 ppm silver. In some embodiments, comprises at least 20 ppm silver. In some embodiments, the composition further comprises at least 25 ppm silver. In some embodiments, comprises no more than 600 ppm silver. In some embodiments, composition comprises no more than 100 ppm silver. In some embodiments, the composition comprises no more than 65 ppm silver.

[0019] In some embodiments, about 50 mg/mL of the composition in water is isotonic with body fluids. In some embodiments, the isotonic solution has an osmolality in the range of about 280 to about 330 mOsm/kg.

[0020] In some embodiments, the composition has a density in the range of about 1.1 to about 1.3 kg/m3.

[0021] Some embodiments disclosed herein include a process for making L-omithine phenyl acetate salt comprising: intermixing an L-ornithine salt, a benzoate salt and a solvent to form an intermediate solution; intermixing phenyl acetate with said intermediate solution; and isolating a composition comprising at least 70% crystalline L-omithine phenyl acetate by weight.

[0022] In some embodiments, the process comprises removing at least a portion of a salt from said intermediate solution before intermixing the phenyl acetate, wherein said salt is not an L-ornithine salt. In some embodiments, the process comprises adding hydrochloric acid before removing at least a portion of the salt.

[0023] In some embodiments, intermixing the L-omithine, the benzoate salt and the solvent comprises: dispersing the L-ornithine salt in water to form a first solution; dispersing the benzoate salt in DMSO to form a second solution; and intermixing said first solution and said second solution to form said solution.

[0024] In some embodiments, the composition comprises at least about 0.10% by weight benzoate salt. In some embodiments, composition comprises no more than 5% by weight benzoate salt. In some embodiments, composition comprises no more than 1% by weight benzoate salt.

[0025] In some embodiments, the L-omithine salt is L-omithine hydrochloride. In some embodiments, the benzoate salt is silver benzoate.

[0026] In some embodiments, the composition comprises at least 10 ppm silver. In some embodiments, composition comprises at least 20 ppm silver. In some embodiments, the composition comprises at least 25 ppm silver. In some embodiments, the composition comprises no more than 600 ppm silver. In some embodiments, the composition comprises no more than 100 ppm silver. In some embodiments, the composition comprises no more than 65 ppm silver.

[0027] In some embodiments, the phenyl acetate is in an alkali metal salt. In some embodiments, the alkali metal salt is sodium phenyl acetate.

[0028] In some embodiments, the composition comprises no more than 100 ppm sodium. In some embodiments, the composition comprises no more than 20 ppm sodium.

[0029] In some embodiments, the L-ornithine is in a halide salt. In some embodiments, the halide salt is L-ornithine hydrochloride.

[0030] In some embodiments, the composition comprises no more than 0.1% by weight chloride. In some embodiments, the composition comprises no more than 0.01% by weight chloride.

[0031] Some embodiments disclosed herein include a composition obtained by any of the processes disclosed herein.

[0032] Some embodiments disclosed herein include a process for making L-omithine phenyl acetate salt comprising: increasing the pH value of a solution comprising an L-omithine salt at least until an intermediate salt precipitates, wherein said intermediate salt is not an L-omithine salt; isolating the intermediate salt from said solution; intermixing phenyl acetic acid with said solution; and isolating L-omithine phenyl acetate salt from said solution.

[0033] In some embodiments, the pH value is increased to at least 8.0. In some embodiments, the pH value is increased to at least 9.0. In some embodiments, increasing the pH value comprises adding a pH modifier selected from the group consisting of sodium hydroxide, potassium hydroxide, sodium methoxide, potassium t-butoxide, sodium carbonate, calcium carbonate, dibutylamine, tryptamine, sodium hydride, calcium hydride, butyllithium, ethylmagnesium bromide or combinations thereof.

[0034] Some embodiments disclosed herein include a method of treating or ameliorating hyperammonemia in a subject by administering a therapeutically effective amount of a crystalline form of L-omithine phenyl acetate salt.

[0035] In some embodiments, the crystalline form is administered orally.

[0036] In some embodiments, the crystalline form is selected from the group consisting of Form I, Form II, Form III, Form V, wherein: Form I exhibits an X-ray powder diffraction pattern having characteristic peaks at approximately 4.9°, 13.2°, 17.4°, 20.8° and 24.4° 2Θ; Form II exhibits an X-ray powder diffraction pattern having characteristic peaks at approximately 6.0°, 13.9°, 14.8°, 17.1°, 17.8° and 24.1° 2Θ; Form III exhibits an X-ray powder diffraction pattern having characteristic peaks at approximately 5.8°, 14.1°, 18.6°, 19.4°, 22.3° and 24.8° 2Θ; and Form V exhibits an X-ray powder diffraction pattern having characteristic peaks at approximately 13.7°, 17.4°, 19.8°, 20.6° and 23.7° 2Θ.

[0037] In some embodiments, the crystalline form is Form I. In some embodiments, the crystalline form is Form II. In some embodiments, the crystalline form is Form III. In some embodiments, the crystalline form is Form V.

[0038] In some embodiments, the at least two crystalline forms selected from the group consisting of Form I, Form II, Form III and Form V, are administered. In some embodiments, the at least two crystalline forms are administered at about the same time.

[0039] In some embodiments, the crystalline form is administered from 1 to 3 times daily. In some embodiments, the therapeutically effective amount is in the range of about 500 mg to about 50 g.

[0040] In some embodiments, the subject is identified as having hepatic encephalopathy. In some embodiments, the subject is identified as having hyperammonemia.

[0041] Some embodiments disclosed herein include a process for making L-omithine phenyl acetate salt comprising: intermixing an L-omithine salt, silver phenyl acetate and a solvent to form a solution, wherein the L-omithine salt is an alkali metal salt; and isolating L-omithine phenyl acetate from said solution.

[0042] Some embodiments disclosed herein include a method of treating or ameliorating hyperammonemia comprising intravenously administering a therapeutically effective amount of a solution comprising L-omithine phenyl acetate, wherein said therapeutically effective amount comprises no more than 500 mL of said solution.

[0043] In some embodiments, the solution comprises at least about 25 mg/mL of L-ornithine phenyl acetate. In some embodiments, the solution comprises at least about 40 mg/mL of L-omithine phenyl acetate. In some embodiments, the solution comprises no more than 300 mg/mL. In some embodiments, the solution is isotonic with body fluid.

[0044] Some embodiments disclosed herein include a method of compressing L-omithine phenyl acetate, the method comprising applying pressure to a metastable form of L-omithine phenyl acetate to induce a phase change.

[0045] In some embodiments, the metastable form is amorphous. In some embodiments, the metastable form exhibits an X-ray powder diffraction pattern comprising at least one characteristic peak, wherein said characteristic peak is selected from the group consisting of approximately 4.9°, 13.2°, 20.8° and 24.4° 2Θ.

[0046] In some embodiments, the pressure is applied for a predetermined time. In some embodiments, the predetermined time is about 1 second or less. In some embodiments, the pressure is at least about 500 psi.

[0047] In some embodiments, the phase change yields a composition having a density in the range of about 1.1 to about 1.3 kg/m3 after applying the pressure.

[0048] In some embodiments, the phase change yields a composition exhibiting an X-ray powder diffraction pattern comprising at least one characteristic peak, wherein said characteristic peak is selected from the group consisting of approximately 6.0°, 13.9°, 14.8°, 17.1°, 17.8° and 24.1° 2Θ.

[0049] Some embodiments disclosed herein include a composition obtained by applying pressure to a metastable form of L-ornithine phenyl acetate to induce a phase change.

BRIEF DESCRIPTION OF THE DRAWINGS

[0050] FIGURE 1 is an X-ray powder diffraction pattern of Form I.

[0051] FIGURE 2 shows differential scanning calorimetry results for Form I.

[0052] FIGURE 3 shows thermogravimetric gravimetric/differential thermal analysis of Form I.

[0053] FIGURE 4 shows the 'H nuclear magnetic resonance spectrum obtained from a sample of Form I.

[0054] FIGURE 5 shows dynamic vapor sorption results for Form I.

[0055] FIGURE 6 is an X-ray powder diffraction pattern of Form II.

[0056] FIGURE 7 shows differential scanning calorimetry results for Form II.

[0057] FIGURE 8 shows thermogravimetric gravimetric/differential thermal analysis of Form II.

[0058] FIGURE 9 shows the 'H nuclear magnetic resonance spectrum obtained from a sample of Form II.

[0059] FIGURE 10 shows dynamic vapor sorption results for Form II.

[0060] FIGURE 11 is an X-ray powder diffraction pattern of Form III.

[0061] FIGURE 12 shows differential scanning calorimetry results for Form ΙΠ.

[0062] FIGURE 13 shows thermogravimetric gravimetric/differential thermal analysis of Form ΙΠ.

[0063] FIGURE 14 shows the 'H nuclear magnetic resonance spectrum obtained from a sample of Form III.

[0064] FIGURE 15 shows dynamic vapor sorption results for Form III.

[0065] FIGURE 16 is an X-ray powder diffraction pattern of Form V.

[0066] FIGURE 17 shows differential scanning calorimetry results for Form V.

[0067] FIGURE 18 shows thermogravimetric gravimetric/differential thermal analysis of Form V.

[0068] FIGURE 19 shows the 'H nuclear magnetic resonance spectrum obtained from a sample of Form V.

[0069] FIGURE 20 shows dynamic vapor sorption results for Form V.

[0070] FIGURE 21 shows the ’H nuclear magnetic resonance spectrum obtained from a sample of L-omithine benzoate.

[0071] FIGURE 22 shows the ]H nuclear magnetic resonance spectrum obtained from a sample of L-ornithine phenyl acetate.

DETAILED DESCRIPTION

[0072] Disclosed herein are methods of making L-omithine phenyl acetate salts, and in particular, crystalline forms of said salt. These methods permit large-scale production of pharmaceutically acceptable forms of L-omithine phenyl acetate using economical processes. Moreover, crystalline forms of L-omithine phenyl acetate, including Forms I, II, III and V are also disclosed. The L-omithine phenyl acetate salts permit intravenous administration with negligible concomitant sodium load, and therefore minimize the amount of i.v. fluid that is required.

[0073] The present application relates to new crystalline forms of L-ornithine phenyl acetate salts, as well as methods of making and using L-omithine phenyl acetate salts. The salt advantageously exhibits long-term stability without significant amounts of sodium or chloride. As a result, L-omithine phenyl acetate is expected to provide an improved safety profile compared to other salts of L-omithine and phenyl acetate. Also, L-omithine phenyl acetate exhibits lower tonicity compared to other salts, and therefore can be administered intravenously at higher concentrations. Accordingly, L-ornithine phenyl acetate is expected to provide significant clinical improvements for the treatment of hepatic encephalopathy.

[0074] The present application also relates to various polymorphs of L-ornithine phenyl acetate. The occurrence of different crystal forms (polymorphism) is a property of some molecules and molecular complexes. Salt complexes, such as L-omithine phenyl acetate, may give rise to a variety of solids having distinct physical properties like melting point, X-ray diffraction pattern, infrared absorption fingerprint and NMR spectrum. The differences in the physical properties of polymorphs result from the orientation and intermolecular interactions of adjacent molecules (complexes) in the bulk solid. Accordingly, polymorphs can be distinct solids sharing the same active pharmaceutical ingredient yet having distinct advantageous and/or disadvantageous physico-chemical properties compared to other forms in the polymorph family.

Method of Making L-Omithine Phenyl Acetate Salt [0075] Some embodiments disclosed herein include a method of making L-ornithine phenyl acetate salt. L-Ornithine phenyl acetate may be produced, for example, through an intermediate salt, such as L-omithine benzoate. As shown in Scheme 1, an L-omithine salt of Formula I can be reacted with a benzoate salt of Formula II to obtain the intermediate L-omithine benzoate.

Scheme 1

[0076] Various salts of L-omithine may be used in the compound of Formula I, and therefore X in Formula I can be any ion capable of forming a salt with L-ornithine other than benzoic acid or phenyl acetic acid. X can be a monoatomic anion, such as, but not limited to, a halide (e.g., fluoride, chloride, bromide, and iodide). X can also be a polyatomic anion, such as, but not limited to, acetate, aspartate, formate, oxalate, bicarbonate, carbonate, bitrate, sulfate, nitrate, isonicotinate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate, p-toluenesulfonate, pamoate (i.e., l,T-methylene-bis-(2-hydroxy-3-naphthoate), phosphate and the like. In some embodiments, X is a monovalent ion. In some embodiments, X is chloride.

[0077] Similarly, the benzoate salt of Formula II is not particularly limited, and therefore Y in Formula II can be any appropriate ion capable of forming a salt with benzoic acid. In some embodiments, Y can be a monoatomic cation, such as an alkali metal ion (e.g., Li+, Na+, and K+) and other monovalent ions (e.g., Ag+). Y may also be a polyatomic cation, such as ammonium, L-arginine, diethylamine, choline, ethanolamine, ΙΗ-imidazole, trolamine, and the like. In some embodiments, Y is an inorganic ion. In some embodiments, Y is silver.

[0078] Many other possible salts of L-omithine and benzoic acid may be used for the compounds of Formulae I and II, respectively, and can readily be prepared by those skilled in the art. See, for example, Bighley L.D., et al., “Salt forms of drugs and absorption,” In: Swarbrick J., Horlan J.C., eds. Encyclopedia of pharmaceutical technology, Vol. 12. New York: Marcel Dekker, Inc. pp. 452-499, which is hereby incorporated by reference in its entirety.

[0079] The intermediate L-ornithine benzoate (i.e., Formula III) can be prepared by intermixing solutions including compounds of Formulae I and II. As an example, the compounds of Formulae I and II may be separately dissolved in water and dimethyl sulfoxide (DMSO), respectively. The two solutions may then be intermixed so that the L-omithine and benzoic acid react to form the salt of Formula III. Alternatively, the two salt compounds can be directly dissolved into a single solution. In some embodiments, L-ornithine and benzoic acid are dissolved in separate solvents, and subsequently intermixed. In some embodiments, L-ornithine is dissolved in an aqueous solution, benzoic acid is dissolved in an organic solvent, and the L-ornithine and benzoic acid solutions are subsequently intermixed.

[0080] Non-limiting examples of solvents which may be used when intermixing L-ornithine and benzoate salts include acetonitrile, dimethylsulfoxide (DMSO), cyclohexane, ethanol, acetone, acetic acid, 1-propanol, dimethylcarbonate, N-methyl-2-pyrrolidone (NMP), ethyl acetate (EtOAc), toluene, isopropyl alcohol (IPA), diisopropoyl ether, nitromethane, water, 1,4 dioxane, tdiethyl ether, ethylene glycol, methyl acetate (MeOAc), methanol, 2-butanol, cumene, ethyl formate, isobutyl acetate, 3-methyl-1 -butanol, anisole, and combinations thereof. In some embodiments, the L-omithine benzoate solution includes water. In some embodiments, the L-ornithine benzoate solution includes DMSO.

[0081] Upon intermixing L-omithine and benzoate salts, counterions X and Y may form a precipitate that can be removed from the intermixed solution using known methods, such as filtration, centrifugation, and the like. In some embodiments, X is chloride, Y is silver, and the reaction produces a precipitate having AgCl. Although Scheme 1 shows the compounds of Formulae I and II as salts, it is also within the scope of the present application to intermix the free base of L-omithine and benzoic acid to form the intermediate of L-omithine benzoate. Consequently, forming and isolating the precipitate is optional.

[0082] The relative amount of L-ornithine and benzoate salts that are intermixed is not limited; however the molar ratio of L-omithine to benzoic acid may optionally be in the range of about 10:90 and 90:10. In some embodiments, the molar ratio of L-omithine benzoate can be in the range of about 30:70 and 30:70. In some embodiments, the molar ratio of L-omithine to benzoate can be in the range of about 40:60 and 60:40. In some embodiments, the molar ratio of L-ornithine to benzoate is about 1:1.

[0083] In embodiments where X and Y are both inorganic ions (e.g., X and Y are chloride and silver, respectively), additional amounts of X-containing salt may be added to encourage further precipitation of the counterion Y. For example, if X is chloride and Y is silver, the molar ratio of L-omithine hydrochloride to silver benzoate may be greater than 1:1 so that an excess of chloride is present relative to silver. Accordingly, in some embodiments, the molar ratio of L-omithine to benzoic acid is greater than about 1:1. Nevertheless, the additional chloride salt is not required to be derived from an L-ornithine salt (e.g., L-omithine hydrochloride). For example, dilute solutions of hydrochloric acid may be added to the solution to further remove silver. Although it is not particularly limited when the additional X-containing salt is added, it is preferably added before the AgCl is initially isolated.

[0084] As shown in Scheme 2, the L-ornithine benzoate can be reacted with a phenyl acetate salt of Formula IV to form L-ornithine phenyl acetate. For example, sodium phenyl acetate can be intermixed with a solution of L-ornithine benzoate to form L-omithine phenyl acetate. Various salts of phenyl acetate may be used, and therefore Z in Formula IV can be any cation capable of forming a salt with phenyl acetate other than benzoic acid or L-omithine. In some embodiments, Z can be a monoatomic cation, such as an alkali metal ion (e.g., Li+, Na+, and K+) and other monovalent ions (e.g., Ag+). Z may also be a polyatomic cation, such as ammonium, L-arginine, diethylamine, choline, ethanolamine, lH-imidazole, trolamine, and the like. In some embodiments, Z is an inorganic ion. In some embodiments, Z is sodium.

[0085] The relative amount of L-ornithine and phenyl acetate salts that are intermixed is also not limited; however the molar ratio of L-omithine to phenyl acetate may optionally be in the range of about 10:90 and 90:10. In some embodiments, the molar ratio of L-omithine to phenyl acetate can be in the range of about 30:70 and 30:70. In some embodiments, the molar ratio of L-ornithine to phenyl acetate can be in the range of about 40:60 and 60:40. In some embodiments, the molar ratio of L-ornithine to benzoic acid is about 1:1.

Scheme 2

[0086] The L-ornithine phenyl acetate of Formula V may then be isolated from solution using known techniques. For example, by evaporating any solvent until the L-omithine phenyl acetate crystallizes, or alternatively by the adding an anti-solvent miscible in the L-omithine phenyl acetate solution until the L-omithine phenyl acetate precipitates from solution. Another possible means for isolating the L-omithine phenyl acetate is to adjust the temperature of the solution (e.g., lower the temperature) until the L-omithine phenyl acetate precipitates. As will be discussed in further detail in a later section, the method of isolating the L-ornithine phenyl acetate affects the crystalline form that is obtained.

[0087] The isolated L-ornithine phenyl acetate may be subjected to various additional processing, such as drying and the like. In some embodiments, L-ornithine phenyl acetate may be subsequently intermixed with a dilute HC1 solution to precipitate residual silver. The L-omithine phenyl acetate may again be isolated from solution using similar methods disclosed above.

[0088] As would be appreciated by a person of ordinary, guided by the teachings of the present application, L-ornithine phenyl acetate may similarly be prepared using an intermediate salt other than L-omithine benzoate. Thus, for example, L-omithine, or a salt thereof (e.g., L-omithine hydrochloride), can be intermixed with a solution having acetic acid. L-Omithine acetate may then be intermixed with phenyl acetic acid, or a salt thereof (e.g., sodium phenyl acetate), to obtain L-omithine phenyl acetate. Scheme 4 illustrates an exemplary process of forming L-omithine phenyl acetate using L-ornithine acetate as an intermediate salt. In some embodiments, the intermediate salt can be a pharmaceutically acceptable salt of L-ornithine. For example, the intermediate L-ornithine salt can be an acetate, aspartate, formate, oxalate, bicarbonate, carbonate, bitrate, sulfate, nitrate, isonicotinate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate, p-toluenesulfonate, pamoate (i.e., l,l'-methylene-bis-(2-hydroxy-3-naphthoate) or phosphate. The free acid of the intermediate is preferably a weaker acid relative to phenyl acetic acid. In some embodiments, the intermediate is an L-ornithine salt with an anion component that exhibits a pKa value that is higher than the pKa value of phenyl acetic acid. As an example, for L-ornithine acetate, acetic acid and phenyl acetic acid exhibit pKa values of about 4.76 and 4.28, respectively.

Scheme 3

[0089] L-Omithine phenyl acetate may also be prepared, in some embodiments, without forming an intermediate salt, such as L-omithine benzoate. Scheme 4 illustrates an exemplary process for preparing L-omithine phenyl acetate without an intermediate salt. A pH modifier may be added to a solution of L-omithine salt (e.g., as illustrated in Scheme 4 by the compound of Formula I) until a salt precipitates from solution, where the salt is not an L-omithine salt. As an example, sodium methoxide (NaOMe) can be added to a solution of L-omithine hydrochloride until sodium chloride precipitates from solution to leave a free base of L-omithine. The precipitate may optionally be isolated from solution using known techniques, such as filtration, centrifugation, and the like. The free base of L-omithine (e.g., as illustrated in Scheme 4 by the compound of Formula I-a) may be intermixed with phenyl acetic acid, or a salt thereof (e.g., as illustrated in Scheme 4 by the compound of Formula IV), to obtain L-ornithine phenyl acetate. The L-omithine phenyl acetate of Formula V may then be isolated as previously described.

Scheme 4

[0090] A pH modifier can include a basic compound, or anhydrous precursor thereof, and/or a chemically protected base. Non-limiting examples of pH modifiers include sodium hydroxide, potassium hydroxide, sodium methoxide, potassium t-butoxide, sodium carbonate, calcium carbonate, dibutylamine, tryptamine, sodium hydride, calcium hydride, butyllithium, ethylmagnesium bromide and combinations thereof. Also, the amount of pH modifier to be added is not particularly limited; however the molar ratio of L-ornithine to pH modifier may optionally be in the range of about 10:90 and 90:10. In some embodiments, the molar ratio of L-omithine to pH modifier can be in the range of about 30:70 and 30:70. In some embodiments, the molar ratio of L-omithine to pH modifier can be in the range of about 40:60 and 60:40. In some embodiments, the molar ratio of L-omithine to pH modifier is about 1:1. The pH modifier may, in some embodiments be added to adjust the pH value to at least about 8.0; at least about 9.0; or at least about 9.5.

[0091] Another process for forming L-omithine phenyl acetate, in some embodiments, includes reacting an alkali metal salt of L-omithine with a phenyl acetate salt. As an example, L-omithine hydrochloride may be intermixed with silver phenyl acetate and a solvent. AgCl may then precipitate and is optionally isolated from the solution. The remaining L-omithine phenyl acetate can also be isolated using known methods. This process can be completed using generally the same procedures and conditions outlined above. For example, the relative molar amounts of L-ornithine to phenyl acetate can be 10:90 to 90:10; 30:70 to 70:30; 40:60 to 60:40; or about 1:1. Also, the L-omithine phenyl acetate may be isolated by evaporating the solvent, adding an antisolvent, and/or reducing the temperature.

Compositions of L-Ornithine Phenyl Acetate [0092] Also disclosed herein are compositions of L-omithine phenyl acetate. The compositions of the present application advantageously have low amounts of inorganic salts, particularly alkali metal salts and/or halide salts, and therefore are particularly suited for oral and/or intravenous administration to patients with hepatic encephalopathy. Meanwhile, these compositions may exhibit similar stability profiles compared to other salts (e.g., mixtures of L-omithine hydrochloride and sodium phenyl acetate). The compositions may, in some embodiments, be obtained by one of the processes disclosed in the present application. For example, any of the disclosed processes using L-omithine benzoate as an intermediate may yield the compositions of the present application.

[0093] The compositions, in some embodiments, can include a crystalline form of L-omithine phenyl acetate (e.g., Forms I, II, III and/or V disclosed herein). In some embodiments, the composition may include at least about 20% by weight of a crystalline form of L-omithine phenyl acetate (preferably at least about 50% by weight, and more preferably at least about 80% by weight). In some embodiments, the composition consists essentially of a crystalline form of L-omithine phenyl acetate. In some embodiments, the composition includes a mixture of at least two (e.g., two, three or four forms) of Forms I, II, III, and V.

[0094] The compositions, in some embodiments, include Form II. For example, the compositions may include at least about 20%; at least about 50%; at least about 90%; at least about 95%; or at least about 99% of Form Π. Similarly, the compositions may also include, for example, Forms I, ΠΙ or V. The compositions may optionally include at least about 20%; at least about 50%; at least about 90%; at least about 95%; or at least about 99% of Forms I, Π, ΠΙ and/or V.

[0095] Also within the scope of the present application are amorphous forms of L-omithine phenyl acetate. Various methods are known in the art for preparing amorphous forms. For example, a solution of L-omithine phenyl acetate may be dried under vacuum by lyophilization to obtain an amorphous composition. See P.C.T.

Application WO 2007/058634, which published in English and designates the U.S., and is hereby incorporated by reference for disclosing methods of lyophilization.

[0096] It is preferred that the composition have low amounts (if any) of alkali and halogen ions or salts, particular sodium and chloride. In some embodiments, the composition comprises no more than about 100 ppm of alkali metals (preferably no more than about 20 ppm, and most preferably no more than about 10 ppm). In some embodiments, the composition comprises no more than about 100 ppm of sodium (preferably no more than about 20 ppm, and most preferably no more than about 10 ppm). In some embodiments, the composition comprises no more than about 0.1% by weight of halides (preferably no more than about 0.01% by weight). In some embodiments, the composition comprises no more than about 0.1% by weight of chloride (preferably no more than about 0.01% by weight).

[0097] The reduced content of alkali metals and halides provides a composition suitable for preparing concentrated isotonic solutions. As such, these compositions can be more easily administered intravenously compared to, for example, administering mixtures of L-omithine hydrochloride and sodium phenyl acetate. In some embodiments, an about 45 to about 55 mg/mL solution of L-omithine phenyl acetate in water (preferably about 50 mg/mL) is isotonic with body fluids (e.g., the solution exhibits an osmolality in the range of about 280 to about 330 mOsm/kg).

[0098] The compositions may also include residual amounts of the anion from an intermediate salt formed during the process of making the L-omithine phenyl acetate composition. For example, some of the processes disclosed herein yield compositions having benzoic acid or a salt thereof. In some embodiments, the composition comprises at least about 0.01% by weight benzoic acid or a salt thereof (preferably at least about 0.05% by weight, and more preferably about 0.1% by weight). In some embodiments, the composition comprises no more than about 3% by weight benzoic acid or a salt thereof (preferably no more than about 1% by weight, and more preferably no more than about 0.5% by weight). In some embodiments, the composition includes a salt, or an acid thereof, in the range of about 0.01% to about 3% by weight (preferably about 0.1% to about 1%), wherein the salt is selected from acetate, aspartate, formate, oxalate, bicarbonate, carbonate, bitrate, sulfate, nitrate, isonicotinate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate, p-toluenesulfonate, pamoate (/. e., l,l'-methylene-bis-(2-hydroxy-3-naphthoate) or phosphate.

[0099] Similarly, a composition prepared using an acetate intermediate may have residual amounts of acetic acid or acetate. In some embodiments, the composition includes at least about 0.01% by weight acetic acid or acetate (preferably at least about 0.05% by weight, and more preferably about 0.1% by weight). In some embodiments, the composition includes no more than about 3% by weight acetic acid or acetate (preferably no more than about 1% by weight, and more preferably no more than about 0.5% by weight).

[0100] The compositions may also include low amounts of silver. Exemplary processes disclosed herein utilize, for example, silver benzoate, but still yield compositions with surprisingly low amounts of silver. Thus, in some embodiments, the composition includes no more than about 600 ppm silver (preferably no more than about 100 ppm, and more preferably no more than about 65 ppm). In some embodiments, the composition includes at least about 10 ppm silver (alternatively at least about 20 or 25 ppm silver).

Pharmaceutical Compositions [0101] The compositions of L-omithine phenyl acetate of the present application may also be formulated for administration to a subject (e.g., a human). L-Omithine phenyl acetate, and accordingly the compositions disclosed herein, may be formulated for administration with a pharmaceutically acceptable carrier or diluent. L-omithine phenyl acetate may thus be formulated as a medicament with a standard pharmaceutically acceptable carrier(s) and/or excipient(s) as is routine in the pharmaceutical art. The exact nature of the formulation will depend upon several factors including the desired route of administration. Typically, L-omithine phenyl acetate is formulated for oral, intravenous, intragastric, subcutaneous, intravascular or intraperitoneal administration.

[0102] The pharmaceutical carrier or diluent may be, for example, water or an isotonic solution, such as 5% dextrose in water or normal saline. Solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, com starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, gum arabic, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Such pharmaceutical preparations may be manufactured in known manners, for example, by means of mixing, granulating, tabletting, sugar-coating, or film-coating processes.

[0103] Liquid dispersions for oral administration may be syrups, emulsions or suspensions. The syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.

[0104] Suspensions and emulsions may contain a carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspensions or solutions for intramuscular injections may contain, together with L-omithine phenyl acetate, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.

[0105] The medicament may consist essentially of L-ornithine phenyl acetate and a pharmaceutically acceptable carrier. Such a medicament therefore contains substantially no other amino acids in addition to L-omithine and phenyl acetate. Furthermore, such a medicament contains insubstantial amounts of other salts in addition to L-omithine phenyl acetate.

[0106] Oral formulations may generally include dosages of L-ornithine phenyl acetate in the range of about 500 mg to about 100 g. Accordingly, in some embodiments, the oral formulation includes the L-omithine phenyl acetate compositions disclosed herein in the range of about 500 mg to about 50 g. In some embodiments, the oral formulation is substantially free of alkali metal salts and halides {e.g., contains no more than trace amounts of alkali metal salts and halides).

[0107] Intravenous formulations may also generally include dosages of L-omithine phenyl acetate in the range of about 500 mg to about 100 g (preferably about 1 g to about 50 g). In some embodiments, the intravenous formulation is substantially free of alkali metal salts and halides (e.g., contains no more than trace amounts of alkali metal salts and halides). In some embodiments, the intravenous formulation has a concentration of about 5 to about 300 mg/mL of L-omithine phenyl acetate (preferably about 25 to about 200 mg/mL, and more preferably about 40 to about 60 mg/mL).

[0108] The composition, or medicament containing said composition, may optionally be placed is sealed packaging. The sealed packaging may reduce or prevent moisture and/or ambient air from contacting the composition or medicament. In some embodiments, the packaging includes a hermetic seal. In some embodiments, the packaging sealed under vacuum or with an inert gas (e.g., argon) within the sealed package. Accordingly, the packaging can inhibit or reduce the rate of degradation for the composition or medicament stored within the packaging. Various types of sealed packaging are known in the art. For example, U.S. Patent Number 5,560,490, is hereby incorporate by reference in its entirety, discloses an exemplary sealed package for medicaments.

Compositions with Improved Density [0109] Applicants have surprisingly found that compositions with greater density may be obtained by applying sufficient pressure to compositions having Form I (described below) to induce a transition to Form II (described below). For example, applying 3 tons of force for 90 minutes to Forms I and II yield densities of 1.197 kg/m3 and 1.001 kg/m3, respectively. Surprisingly, Form I converted to Form II under these conditions; therefore the greater density appears to be explained by the different crystalline form as the starting material.

[0110] Accordingly, disclosed herein are methods of increasing the density of an L-omithine phenyl acetate composition having Form I by applying pressure to the composition sufficient to induce a transition to Form II. The appropriate amount of force or pressure to induce the phase change may vary with the amount of time the force or pressure is applied. Thus, a person of ordinary skill, guided by the teachings of the present application, can determine appropriate amounts of pressure and time to induce the phase change. In some embodiments, at least about 1 ton of force is applied (preferably at least about 2 tons, and more preferably about 3 tons). In some embodiments, at least about 500 psi of pressure is applied (preferably at least about 1000 psi, and more preferably at least about 2000 psi).

[0111] The amount of time for applying pressure is not particularly limited, and as discussed above, will vary depending upon the amount time. For example, when applying large forces (e.g., 10 tons) to a typical tablet-sized punch, the time may be about 1 second or less. In some embodiments, the time for apply pressure is a predetermined time. The time may be, for example, about 0.1 seconds; about 1 second; at least about 1 minute; at least about 5 minutes; or at least about 20 minutes.

[0112] In some embodiments, the composition includes at least about 10% by weight of Form I. In some embodiments, the composition includes at least about 30% by weight of Form I.

[0113] Without being bound to any particular theory, Applicants believe the greater density may result, at least in part, from ethanol solvate component present in Form I. Applying pressure to the solvate may facilitate forming a denser structure with fewer defects (e.g., grain boundaries). Consequently, in some embodiments, methods of increasing the density of an L-omithine phenyl acetate composition having solvate components include applying pressure to the composition sufficient to induce a transition to Form II. In some embodiments, the pressure is at least about 500 psi (preferably at least about 1000 psi, and more preferably at least about 2000 psi). In some embodiments, the time for apply pressure is a predetermined time. In some embodiments, the composition includes at least about 10% of the solvate form (preferably at least about 30%, and more preferably at least about 50%).

[0114] The compositions of L-omithine phenyl acetate disclosed herein may therefore have higher densities compared to compositions obtain by, for example, precipitating a crystalline form. In some embodiments, the composition has a density of at least about 1.1 kg/m3 (preferably at least about 1.15 kg/m3, and more preferably at least about 1.18 kg/m3). In some embodiments, the composition has a density of no more than about 1.3 kg/m3 (preferably no more than about 1.25 kg/m3, and more preferably no more than about 1.22 kg/m ). In some embodiments, the composition has a density of about 1.2 kg/m3.

Crystalline Forms of L-Omithine Phenyl Acetate [0115] Also disclosed herein are crystalline forms of L-omithine phenyl acetate, and in particular, crystalline Form I, Form II, Form III, and Form V. L-Omithine phenyl acetate may, in some embodiments, be obtained using the processes disclosed above and then crystallized using any of the methods disclosed herein.

Form I

[0116] The precise conditions for forming crystalline Form I may be empirically determined and it is only possible to give a number of methods which have been found to be suitable in practice.

[0117] Thus, for example, crystalline Form I may generally be obtained by crystallizing L-ornithine phenyl acetate under controlled conditions. As an example, precipitating L-omithine phenyl acetate from a saturated solution by adding ethanol at reduced temperatures (e.g., 4° or-21° C). Exemplary solvents for the solution that yield crystalline Form I upon adding ethanol include, but are not limited to, cyclohexanone, 1-propanol, diemthylcarbonate, N-methylpyrrolidine (NMP), diethyl ether, 2-butanol, cumene, ethyl formate, isobutyl acetate, 3-nethyl-l-butanol, and anisole.

[0118] Accordingly, in the context of the processes for making L-ornithine phenyl acetate disclosed above, the process can yield Form I by utilizing particular isolation methods. For example, L-ornithine phenyl acetate may be isolated by adding ethanol at reduced temperature to yield Form I.

[0119] Crystalline Form I was characterized using various techniques which are described in further detail in the experimental methods section. FIGURE 1 shows the crystalline structure of Form I as determined by X-ray powder diffraction (XRPD). Form I, which may be obtained by the methods disclosed above, exhibits characteristic peaks at approximately 4.9°, 13.2°, 17.4°, 20.8° and 24.4° 2Θ. Thus, in some embodiments, a crystalline form of L-omithine phenyl acetate has one or more characteristic peaks (e.g., one, two, three, four or five characteristic peaks) selected from approximately 4.9°, 13.2°, 17.4°, 20.8°,and 24.4° 2Θ.

[0120] As is well understood in the art, because of the experimental variability when X-ray diffraction patterns are measured on different instruments, the peak positions are assumed to be equal if the two theta (2Θ) values agree to within 0.2° (i.e., ± 0.2°). For example, the United States Pharmacopeia states that if the angular setting of the 10 strongest diffraction peaks agree to within ± 0.2° with that of a reference material, and the relative intensities of the peaks do not vary by more than 20%, the identity is confirmed. Accordingly, peak positions within 0.2° of the positions recited herein are assumed to be identical.

[0121] FIGURE 2 shows results obtained by differential scanning calorimetry (DSC) for Form I. These results indicate an endotherm at 35° C, which is possibly associated with a desolvation and/or dehydration to Form II. A second transition at about 203° C indicates the melting point for the crystal. To explore the possible existence of a desolvation and/or dehydration transition, Form I was analyzed by thermogravimetric gravimetric/differential thermal analysis (TG/DTA), which is shown in FIGURE 3. Form I exhibits a 11.28% weight loss at about 35° C, and therefore these results further suggest that Form I exhibits a desolvation and/or dehydration transition at about 35° C. The melting point of about 203° C could also be observed by TGA testing. Accordingly, in some embodiments, the crystalline form of L-omithine phenyl acetate is characterized by differential scanning calorimetry as having an endotherm at about at about 35° C. In some embodiments, a crystalline form of L-omithine phenyl acetate exhibits a weight loss of about 11% at about 35° C, as determined by TGA. In some embodiments, a crystalline form of L-omithine phenyl acetate exhibits a melting point of about 203° C.

[0122] FIGURE 4 shows nuclear magnetic resonance (NMR) integrals and chemical shifts for Form I. The integrals confirm the presence of L-omithine phenyl acetate: 7.5 (aromatic CH), 3.8 (CH adjacent to NFL), 3.6 (CH2 unit of phenyl acetate), 3.15 (CH2 adjacent to NH2) and 1.9 (aliphatic CH2 units) ppm (integrals: 5:1:2:2:4 protons; 1.2, 0.25, 0.5, 0.5, 1.0). Amine protons and hydroxyl protons were not observed due to proton exchange at both the zwitterion and site of salt formation. Meanwhile, FIGURE 5 shows dynamic vapor sorption (DVS) results for Form I, and show a water uptake of about 0.2% by weight. XRPD results following DVA analysis (not shown) confirm that Form I did not transition to a different polymorph. Form I can therefore be characterized as non-hygroscopic and stable over a wide range of humidity.

[0123] A 7-day stability study of Form I at 40°C/75%RH indicated that a transformation to Form II occurred under these conditions. Form I also converts to Form II at elevated temperatures (e.g., 80° or 120° C), with or without applying a vacuum, after 7 or 14 days. Accordingly, Form I is metastable.

[0124] Single crystal x-ray diffraction (SXRD) was also used to determine the structure of Form I at -20° and -123° C, and the results are summarized in TABLES 1 and 2. The results confirm that Form I is a solvate having ethanol and water molecules within the unit cell. In some embodiments, a crystalline form of L-ornithine phenyl acetate can be represented by the formula Ci5H28N206. In some embodiments, a crystalline form of L-ornithine phenyl acetate can be represented by the formula [C5Hi3N202][CgH702]EtOH.H20. In some embodiments, a crystalline form of L-ornithine phenyl acetate exhibits a single crystal X-ray crystallographic analysis with crystal parameters approximately equal to the following: unit cell dimensions of a=5.3652(4) A, b=7.7136(6) A, c=20.9602(18) A, α=90°, β=94.986(6)°, γ=90°; a monoclinic crystal system, and a P2i space group.

TABLE 1 - Crystallographic Data of Form I Collected at -20° C

TABLE 2 - Crystallographic Data of Form I Collected at -123° C

Form Π [0125] The precise conditions for forming crystalline Form II may be empirically determined and it is only possible to give a number of methods which have been found to be suitable in practice.

[0126] Thus, for example, crystalline Form II may be prepared by crystallization under controlled conditions. Crystalline Form II can be prepared by, for example, evaporating a saturated organic solution of L-omithine phenyl acetate. Nonlimiting examples of organic solutions that may be used to obtain Form II include ethanol, acetone, benzonitrile, dichloromethane (DCM), dimethyl sulfoxide (DMSO), ethyl acetate (EtOAc), acetonitrile (MeCN), methyl acetate (MeOAc), nitromethane, tert-butyl methyl ether (TBME), tetrahydrofuran, and toluene. Other solvents may yield a mixture of Form I and II, such as, but not limited to, 1,4 dioxane, 1-butanol, cyclohexane, IPA, THF, MEK, MeOAc and water.

[0127] Form II can also be obtained by precipitating L-omithine phenyl acetate from a saturated organic solution by adding an anti-solvent for L-omithine phenyl acetate, such as IPA. Form II may be precipitated over a broad range of temperatures (e.g., room temperature, 4° C, and -21° C). Non-limiting examples of suitable solvents for the saturated organic solution include cyclohexanone, 1-propanol, dimethyl carbonate, N-methylpyrrolidone (NMP), diisopropyl ether, diethyl ether, ethylene glycol, dimethylformamide (DMF), 2-butanol, cumene, isobutyl acetate, 3-methyl-l-butanol, and anisole. Alternatively, the same listed solvents (e.g., cyclohexanone) can be used to form a solution of L-omithine phenyl acetate, and Form II may be precipitated by adding ethanol at ambient conditions. As another example, Form II may also be obtained by forming a slurry of L-omithine phenyl acetate with the listed organic solvents and cycling the temperature between 25° and 40° C every 4 hours for about 18 cycles (or 72 hours).

[0128] Accordingly, in the context of the processes for making L-ornithine phenyl acetate disclosed above, the process can yield Form II by utilizing particular isolation methods. For example, L-omithine phenyl acetate may by isolated by adding IPA, or evaporating the organic solvent, to yield Form II.

[0129] FIGURE 6 shows the crystalline structure of Form II as determined by XRPD. Form II, which may be obtained by the methods disclosed above, exhibits characteristic peaks at approximately 6.0°, 13.9°, 14.8°, 17.1°, 17.8° and 24.1° 2Θ. Thus, in some embodiments, a crystalline form of L-ornithine phenyl acetate has one or more characteristic peaks (e.g., one, two, three, four, five or six characteristic peaks) selected from approximately 6.0°, 13.9°, 14.8°, 17.Γ, 17.8° and 24.12° Θ.

[0130] FIGURE 7 shows results obtained by differential scanning calorimetry (DSC) for Form II. These results indicate a melting point of about 202° C, which is approximately the same as the melting point for Form I. This suggests that Form I transitions to Form Π upon heating above about 35° C. Form II was also analyzed using TG/DTA, as shown in FIGURE 8, and exhibits an about 9.7% weight loss associated with residual solvent. The melting point of about 202° C could also be observed by TGA testing. Accordingly, in some embodiments, a crystalline form of L-omithine phenyl acetate exhibits a melting point of about 202° C.

[0131] A 7-day stability study of Form Π at 40°C/75%RH failed to produce an observable phase change. In fact, Form II was stable over 14 days when exposed to elevated temperatures, varying pHs, UV light or oxygen. Accordingly, Form II is considered stable.

[0132] FIGURE 9 shows nuclear magnetic resonance (NMR) integrals and chemical shifts for Form II. The integrals confirm the presence of L-ornithine phenyl acetate: 7.5 (aromatic CH), 3.8 (CH adjacent to NH2), 3.6 (CH2 unit of phenylacetate), 3.15 (CH2 adjacent to NH2) and 1.9 (aliphatic CH2 units) ppm (integrals: 5:1:2:2:4 protons; 7.0, 1.4, 2.9, 3.0, 5.9). Amine protons and hydroxyl protons were not observed due to proton exchange at both the zwitterion and site of salt formation. Meanwhile, FIGURE 10 shows dynamic vapor sorption (DVS) results for Form II, and show a water uptake of about 0.3% by weight. XRPD results following DVA analysis (not shown) confirm that Form II did not transition to a different polymorph. Form II can therefore be characterized as non-hygroscopic and stable over a wide range of humidity.

[0133] Single crystal x-ray diffraction (SXRD) was also used to determine the structure of Form II at 23° and -123° C, and the results are summarized in TABLES 3 and 4. The results demonstrate that Form II is anhydrous and therefore structurally different from Form I. In some embodiments, a crystalline form of L-omithine phenyl acetate can be represented by the formula C13H20N2O4. In some embodiments, a crystalline form of L-omithine phenyl acetate can be represented by the formula [C5H13N2O2HC8H7O2]. In some embodiments, a crystalline form of L-omithine phenyl acetate exhibits a single crystal X-ray crystallographic analysis with crystal parameters approximately equal to the

following: unit cell dimensions of a = 6.594(2) A, a= 90°, b = 6.5448(18) A, β= 91.12(3)°, c = 31.632(8) A, γ= 90°; a monoclinic crystal system; and a P2i space group. TABLE 3 - Crystallographic Data of Form II Collected at 23° C

TABLE 4 - Crystallographic Data of Form II Collected at -123° C

Form III

[0134] The precise conditions for forming crystalline Form III may be empirically determined and it is only possible to give a number of methods which have been found to be suitable in practice.

[0135] Thus, for example, Form III may be obtained by placing a saturated solution of L-omithine phenyl acetate in a cooled temperature environment of about -21° C, where the solution is a mixture of acetone and water (e.g., equal parts volume of acetone and water). As another example, adding IPA to a saturated solution of L-ornithine phenyl acetate in 2-butanol can yield Form III when completed at ambient conditions. Furthermore, Form III may be obtained, for example, by adding IPA to a saturated solution of L-omithine phenyl acetate in isobutyl acetate when completed at reduced temperatures of about -21° C.

[0136] Accordingly, in the context of the processes for making L-ornithine phenyl acetate disclosed above, the process can yield Form III by utilizing particular solvents and isolation methods. For example, L-omithine phenyl acetate may be formed within a mixture of acetone and water, and subsequently placed in a cool environment of about-21° C to yield Form ΙΠ.

[0137] FIGURE 11 shows the crystalline structure of Form III as determined by XRPD. Form III, which may be obtained by the methods disclosed above, exhibits characteristic peaks at approximately 5.8°, 14.1°, 18.6°, 19.4°, 22.3° and 24.8° 2Θ. Thus, in some embodiments, a crystalline form of L-omithine phenyl acetate has one or more characteristic peaks (e.g., one, two, three, four, five or six characteristic peaks) selected from approximately 5.8°, 14.1°, 18.6°, 19.4°, 22.3° and 24.8° 2Θ.

[0138] FIGURE 12 shows results obtained by differential scanning calorimetry (DSC) for Form III. These results indicate a melting point of about 203° C, which is approximately the same as the melting points for Form I and Form II. Additionally, Form ΙΠ exhibits an endotherm at about 40° C. Form III was also analyzed using TG/DTA, as shown in FIGURE 13, and exhibits no significant weight loss before the melting point. Form ΠΙ may therefore be characterized as anhydrous. The melting point of about 203° C could also be observed by TGA testing. Accordingly, in some embodiments, a crystalline form of L-omithine phenyl acetate exhibits a melting point of about 203° C. In some embodiments, a crystalline form of L-omithine phenyl acetate is characterized by differential scanning calorimetry as having an endotherm at about 40° C. In some embodiments, a crystalline form of L-omithine phenyl acetate is anhydrous.

[0139] A 7-day stability study of Form III at 40°C/75%RH indicated that a transformation to Form II occurred under these conditions. In contrast, Form II is stable at elevated temperatures, with or without vacuum, for periods of 7 or 10 days. Accordingly, Form III is most likely metastable, but more stable than Form I.

[0140] FIGURE 14 shows nuclear magnetic resonance (NMR) integrals and chemical shifts for Form III. The integrals confirm the presence of L-omithine phenyl acetate: 7.5 (aromatic CH), 3.8 (CH adjacent to NH2), 3.6 (CH2 unit of phenyl acetate), 3.15 (CH2 adjacent to NH2) and 1.9 (aliphatic CH2 units) ppm (integrals: 5:1:2:2:4 protons; 4.2, 0.8, 1.7, 1.7, 3.0). Amine protons and hydroxyl protons were not observed due to proton exchange at both the zwitterion and site of salt formation. Meanwhile, FIGURE 15 shows dynamic vapor sorption (DVS) results for Form III, and show a water uptake of about 2.0% by weight. XRPD results following DVS analysis (not shown) confirm that Form III did not transition to a different polymorph. Form III therefore exhibits greater water uptake compared to Forms I and II; however Form III is still characterized as non-hygroscopic and stable over a wide range of humidity at room temperature.

Form V

[0141] The precise conditions for forming crystalline Form V may be empirically determined and it is only possible to give a number of methods which have been found to be suitable in practice.

[0142] Thus, for example, Form V may be obtained by placing a saturated solution of L-ornithine phenyl acetate in a cooled temperature environment of about -21° C, where the solution is cyclohexanone. As another example, the same saturated solution may yield Form V when evaporating the solvent.

[0143] Form V also forms from saturated solutions of L-omithine phenyl acetate having diisopropyl ether as a solvent. For example, a saturated solution having a solvent ratio of about 1 to 2 of diisopropyl ether and IPA will yield Form V when placed in a cooled temperature environment of about 4° C. Similarly, a solution having only the solvent diisopropyl ether can yield Form V when placed in a cooled temperature environment of about -21° C.

[0144] FIGURE 16 shows the crystalline structure of Form V as determined by XRPD. Form V, which may be obtained by the methods disclosed above, exhibits characteristic peaks at approximately 13.7°, 17.4°, 19.8°, 20.6° and 23.7° 2Θ. Thus, in some embodiments, a crystalline form of L-omithine phenyl acetate has one or more characteristic peaks (e.g., one, two, three, four, or five characteristic peaks) selected from approximately 13.7°, 17.4°, 19.8°, 20.6° and 23.7° 2Θ.

[0145] FIGURE 17 shows results obtained by differential scanning calorimetry (DSC) for Form V. These results indicate a melting point of about 196° C, which is below the melting point of other forms. Form V also exhibits an endotherm at about 174° C. Form V was also analyzed using thermal gravimetric analysis (TGA), as shown in FIGURE 18, and exhibits no significant weight loss before the melting point. Form V may therefore be characterized as anhydrous. The melting point of about 196° C could also be observed by TGA testing. Accordingly, in some embodiments, a crystalline form of L-omithine phenyl acetate exhibits a melting point of about 196° C. In some embodiments, a crystalline form of L-omithine phenyl acetate is characterized by differential scanning calorimetry as having an endotherm at about 174° C. In some embodiments, a crystalline form of L-omithine phenyl acetate is anhydrous.

[0146] FIGURE 19 shows nuclear magnetic resonance (NMR) integrals and chemical shifts for Form V. The integrals confirm the presence of L-ornithine phenyl acetate: 7.5 (aromatic CH), 3.8 (CH adjacent to NH2), 3.6 (CH2 unit of phenyl acetate), 3.15 (CH2 adjacent to NH2) and 1.9 (aliphatic CH2 units) ppm (integrals: 5:1:2:2:4 protons; 4.2, 0.8, 1.7, 1.7, 3.0). Amine protons and hydroxyl protons were not observed due to proton exchange at both the zwitterion and site of salt formation. Meanwhile, FIGURE 19 shows dynamic vapor sorption (DVS) results for Form V, and show a water uptake of about 0.75% by weight. XRPD results following DVS analysis (not shown) suggest that Form V transitioned to Form II, but the chemical composition was unchanged. Form V is therefore characterized as non-hygroscopic, but not stable over a wide range of humidity.

[0147] A 7-day stability study of Form V at 40°C/75%RH indicated that a transformation to Form II occurred under these conditions; however the chemical composition was unchanged. Accordingly, Form V is most likely metastable.

Methods of Treating Liver Decompensation or Hepatic Encephalopathy [0148] L-Ornithine phenyl acetate, and accordingly any of the compositions of L-ornithine phenyl acetate disclosed herein, may be administered to a subject for treating or ameliorating the onset of liver decompensation or hepatic encephalopathy. L-Ornithine phenyl acetate can thus be administered to improve the condition of a subject, for example a subject suffering from chronic liver disease following a precipitating event. As another example, L-omithine phenyl acetate may be administered to combat or delay the onset of liver decompensation or hepatic encephalopathy.

[0149] L-Omithine phenyl acetate may be administered in combination to a subject for treatment of hepatic encephalopathy. L-Omithine phenyl acetate may be administered to improve the condition of a patient suffering from hepatic encephalopathy. L-Ornithine phenyl acetate may be administered to alleviate the symptoms associated with hepatic encephalopathy. L-Omithine phenyl acetate may be administered to combat hepatic encephalopathy. L-Omithine phenyl acetate may be administered to prevent or reduce the likelihood of an initial hepatic encephalopathic episode in a person at risk for hepatic encephalopathic episodes. L-Omithine phenyl acetate may be administered to lessen the severity of an initial hepatic encephalopathic episode in a person at risk for hepatic encephalopathic episodes. L-Omithine phenyl acetate may be administered to delay an initial hepatic encephalopathic episode in a person at risk for hepatic encephalopathic episodes.

[0150] Development of liver decompensation and hepatic encephalopathy commonly involves "precipitating events" (or "acute attacks"). Such precipitating events include gastrointestinal bleeding, infection (sepsis), portal vein thrombosis and dehydration. The onset of such an acute attack is likely to lead to hospitalization. The patient may suffer one of these acute attacks or a combination of these acute attacks.

[0151] A subject who has had or is suspected of having had an acute attack is treated according to the invention with L-ornithine phenyl acetate to prevent or reduce the likelihood of progression of the liver to the decompensated state. Consequently, L-omithine phenyl acetate can prevent or reduce the likelihood of the medical consequences of liver decompensation such as hepatic encephalopathy. L-Omithine phenyl acetate may be used to preserve liver function. Use of L-omithine phenyl acetate may thus extend the life of a patient with liver disease. In one embodiment, the metabolic consequences of a gastrointestinal bleed such as hyperammonemia, hypoisoleucemia and reduced protein synthesis in the post-bleeding period are prevented.

[0152] Typically, treatment of subjects may begin as soon as possible after the onset or the suspected onset of a precipitating event (acute attack). Preferably, treatment of the subject begins prior to repeated acute attacks. More preferably, treatment of the subject begins following the first acute attack. Thus, in some embodiments, the subject treated with L-omithine phenyl acetate is identified as having the onset or the suspected onset of a precipitating event (acute attack).

[0153] Treatment is typically given promptly after the start of an acute attack. Treatment may begin after the symptom(s) of an acute attack or suspected acute attack have been detected e.g. by a medic such as a physician, a paramedic or a nurse. Treatment may begin upon hospitalization of the subject. Treatment may thus begin within 6 hours, within 3 hours, within 2 hours or within 1 hour after the symptom(s) of an acute attack or suspected acute attack have been detected. Treatment of the subject may therefore begin from 1 to 48 hours, for example from 1 to 36 hours or from 1 to 24 hours after the symptom(s) of an acute attack or suspected acute attack have been detected.

[0154] Treatment may occur for up to 8 weeks, for example up to 6 weeks, up to 4 weeks or up to 2 weeks after the symptom(s) of an acute attack or suspected acute attack have been detected. Treatment may therefore occur for up to 48 hours, for example for up to 36 hours or for up to 24 hours after the symptom(s) of an acute attack or suspected acute attack have been detected. Typically, treatment occurs to the time when recovery from the acute precipitating event is evident.

[0155] L-Omithine phenyl acetate may also be used to treat or ameliorate hyperammonemia. Thus, L-ornithine phenyl acetate may be administered to patients identified as having excess ammonia levels in the blood, or patients exhibiting symptoms of excess ammonia in the blood. L-Ornithine phenyl acetate may also be administered to reduce the risk of hyperammonemia. In some embodiments, L-ornithine phenyl acetate can be administered daily, for an indefinite period of time. For example, daily dosages may be administered for the life of the patient, or until a physician determines the patient no longer exhibits a risk for hyperammonemia. In some embodiments, a therapeutically effective amount of L-omithine phenyl acetate is administered to reduce the risk of hyperammonemia. In some embodiments, a therapeutically effective amount of L-omithine phenyl acetate is administered orally for the prophylaxis of hyperammonemia.

[0156] A therapeutically effective amount of L-ornithine phenyl acetate is administered to the subject. As will be readily apparent to one skilled in the art, the useful in vivo dosage to be administered and the particular mode of administration will vary depending upon the age, weight, the severity of the affliction, and mammalian species treated, the particular compounds employed, and the specific use for which these compounds are employed. (See e.g., Fingl et al. 1975, in “The Pharmacological Basis of Therapeutics”, which is hereby incorporated herein by reference in its entirety, with particular reference to Ch. 1, p. 1). The determination of effective dosage levels, that is the dosage levels necessary to achieve the desired result, can be accomplished by one skilled in the art using routine pharmacological methods. Typically, human clinical applications of products are commenced at lower dosage levels, with dosage level being increased until the desired effect is achieved. Alternatively, acceptable in vitro studies can be used to establish useful doses and routes of administration of the compositions identified by the present methods using established pharmacological methods.

[0157] A typical dose of L-ornithine phenyl acetate may be from about 0.02 to about 1.25 g/kg of bodyweight (preferably from about 0.1 to about 0.6 g/kg of bodyweight). A dosage may therefore be from about 500 mg to about 50 g (preferably about 5 g to about 40 g, and more preferably about 10 g to about 30 g).

[0158] A single daily dose may be administered. Alternatively, multiple doses, for example two, three, four or five doses may be administered. Such multiple doses may be administered over a period of one month or two weeks or one week. In some embodiments, a single dose or multiple doses such as two, three, four or five doses may be administered daily.

EXAMPLES AND EXPERIMENTAL METHODS

[0159] Additional embodiments are disclosed in further detail in the following examples, which are not in any way intended to limit the scope of the claims. X-rav Powder Diffraction (XRPD) [0160] XRPD analysis was carried out on a Bruker D8 advance or Seimens D5000, scanning the samples between 4° and 50° 2Θ. In embodiments using the Bruker D8 device, approximately 5 mg of a sample was gently compressed on the XRPD zero back ground single 96 well plate sample holder. The sample was then loaded into a Bruker D8-Discover diffractometer in transmission mode and analysed using the following experimental conditions.

[0161] Operator D8-Discover [0162] Raw Data Origin BRUKER-binary V3 (.RAW) [0163] Scan Axis Gonio [0164] Start Position [°2Θ.] 4.0000 [0165] End Position [°20.] 49.9800 [0166] Step Size [°20.] 0.0200 [0167] Scan Step Time [s] 39.1393 [0168] Scan Type Continuous [0169] Offset [°2Θ.] 0.0000 [0170] Divergence Slit Type Fixed [0171] Divergence Slit Size [°] 2.0000 [0172] Specimen Length [mm] 10.00 [0173] Receiving Slit Size [mm] 0.1000 [0174] Measurement Temperature [°C] 25.00 [0175] Anode Material Cu [0176] K-Alpha 1 [A] 1.54060 [0177] K-Alpha2 [A] 1.54443 [0178] K-Beta [A] 1.39225 [0179] K-A2/K-A1 Ratio 0.50000

[0180] Generator Settings 40 mA, 40 kV

[0181] Diffractometer Type Unknown [0182] Diffractometer Number 0 [0183] Goniometer Radius [mm] 250.00 [0184] Dist. Focus-Diverg. Slit [mm] 91.00 [0185] Incident Beam Monochromator No [0186] Spinning No [0187] In embodiments using the Seimens D5000 device, approximately 5 mg of sample was gently compressed on glass slide containing a thin layer of holding grease. The sample was then loaded into a Seimens D5000 diffractometer running in reflection mode and analysed, whilst spinning, using the following experimental conditions.

[0188] Raw Data Origin Siemens-binary V2 (.RAW) [0189] Start Position [°2Θ.] 3.0000 [0190] End Position [°20.] 50.000 [0191] Step Size [°20.] 0.0200 [0192] Scan Step Time [s] 0.8 [0193] Scan Type Continuous [0194] Offset [°2Θ.] 0.0000 [0195] Divergence Slit Type Fixed [0196] Divergence Slit Size [°] 1.0000 [0197] Specimen Length [mm] various [0198] Receiving Slit Size [mm] 0.2000 [0199] Measurement Temperature [°C] 20.00 [0200] Anode Material Cu [0201] K-Alphal [A] 1.54060 [0202] K-Alpha2 [A] 1.54443 [0203] K-Beta [A] 1.39225 [0204] K-A2/K-A1 Ratio 0.50000 (nominal)

[0205] Generator Settings 40 mA, 40 kV

[0206] Diffractometer Type d5000 [0207] Diffractometer Number 0 [0208] Goniometer Radius [mm] 217.50 [0209] Incident Beam Monochromator No [0210] Diffracted Beam Monochromator (Graphite) [0211] Spinning Yes

Single Crystal X-rav Diffraction ISXRDl [0212] All measurements were carried out using a Bruker Smart Apex diffractometer operating with Mo-Κα radiation. Unless otherwise specified the data were obtained in 60 ω-scan 10 s images collected in three separate settings of 20 and φ. Differential Scanning Calorimetry (OSC) [0213] Approximately 5 mg of sample was weighed into an aluminium DSC pan and sealed with a pierced aluminium lid (non-hermetically). The sample pan was then loaded into a Seiko DSC6200 (equipped with a cooler), cooled, and held at 25 °C. Once a stable heat-flow response was obtained, the sample and reference were then heated to about 250 °C at a scan rate of 10 °C/min and the resulting heat flow response monitored. Prior to analysis, the instrument was temperature and heat-flow calibrated using an indium reference standard. Sample analysis was carried out by Muse measurement software where the temperatures of thermal events were quoted as the onset temperature, measured according to the manufacturer’s specifications.

Thermogravimetric Gravimetric/Differential Thermal Analysis (TG/DTA) [0214] Approximately 5 mg of sample was weighed into an aluminium pan and loaded into a simultaneous thermogravimetric/differential thermal analyser (DTA) and held at room temperature. The sample was then heated at a rate of 10 °C/min from 25 °C to 300 °C during which time the change in sample weight was monitored along with any thermal events (DTA). Nitrogen was used as the purge gas, at a flow rate of 20 cm3/min. Prior to analysis the instrument was weight and temperature calibrated using a 100 mg reference weight and an indium reference standard, respectively.

Dynamic Vapor Sorption (DVS) [0215] Approximately 10 mg of sample was placed into a wire-mesh vapor sorption balance pan and loaded into a DVS-1 dynamic vapor sorption balance supplied by Scientific and Medical Systems (SMS). The sample was then dried by maintaining a 0% humidity environment until no further weight change was recorded. The sample was then subjected to a ramping profile from 0 - 90% relative humidity (RH) at 10% increments, maintaining the sample at each step until a stable weight had been achieved (99.5% step completion). After completion of the sorption cycle, the sample was then dried using the same procedure. The weight change during the sorption/desorption cycles were then plotted, allowing for the hygroscopic nature of the sample to be determined. 'H Nuclear Magnetic Resonance (NMR] [0216] ipj nmr was performed on a Bruker AC200. An NMR of each sample was performed in d-fbO and each sample was prepared to about 5 mg concentration. The NMR spectra for L-omithine benzoate and L-omithine phenyl acetate are provided in FIGURES 21 and 22, respectively.

Solubility Approximations [0217] Approximately, 25 mg portions of the sample were placed in vials 5 volume increments of the appropriate solvent system were added. Between each addition, the mixture was checked for dissolution and if no dissolution was apparent, the mixture was warmed to 50°C, and checked again. The procedure was continued until dissolution was observed or when 100 volumes of solvent had been added. HPLC Solubility Determinations [0218] Slurries of each solvent were prepared and the samples shaken for about 48 hrs at 25°C. Each sample was then drawn through a filter, and the filtrate transferred to an HPLC vial for analysis. From the data the solubility of L-ornithine phenyl acetate for each solvent was determined.

Temperature Cycling Experiments [0219] Using the information gathered from the solubility approximations, slurries of the sample were prepared in 24 selected solvent systems. The slurries were temperature cycled at 40°C or 25°C in 4 hour cycles for a period of 72 hours. The solids were visually checked for any obvious signs of degradation (i.e. color changes) and then, if not degraded, isolated by filtration. The solids were allowed to dry at ambient conditions for about 24 hours prior to analysis.

Crash Cooling Experiments [0220] Crash cooling experiments were performed by placing saturated solutions of the sample, in the 24 selected solvent systems, in environments of 4°C and -21°C for about 48 hours. Any solid material was recovered and the solids were allowed to dry at ambient conditions for about 24 hours prior to analysis.

Evaporation Experiments [0221] Evaporation experiments were conducted by allowing saturated solutions of the sample to evaporate freely at ambient conditions. The solid material was then recovered after the material had evaporated to dryness and analyzed.

Anti-solvent Addition Experiments [0222] Anti-solvent addition experiments were conducted by adding antisolvent to saturated solutions of the sample. The addition was continued until there was no further precipitation and the samples adjusted to various temperature for 24 hours: elevated, ambient, 4° C or -21°. The solid was then isolated and dried at ambient conditions for about 24 hours prior to analysis.

Polarized Light Microscopy (PL1V0 [0223] The presence of crystallinity (birefringence) was determined using a Leica Leitz DMRB polarised optical microscope equipped with a high resolution Leica camera and image capture software (Firecam V.1.0). All images were recorded using a lOx objective, unless otherwise stated.

Silver Analysis [0224] All silver analysis was carried out on an Agilent 7500ce ICP-MS. Intrinsic Dissolution Rates [0225] Approximately 100 mg of each form was compressed into discs by placing the material into a die (diameter 12 mm) and compressing the die under 5 tons of pressure in a hydraulic press for about 2 minutes. The dissolution instrument, Sotax AT7 conforms to EP2 and USP2 in which paddles were used to stir the media. Each form was tested under the following pH conditions; 1.0, 4.5 and 6.7, in the stationary disc mode (i.e. discs were added at time=0 seconds and allowed to sink to the bottom of the media). 1 cm3 aliquots of media were extracted from the dissolution pots at times 10, 20, 30, 40, 50, 60, 70, 80 and 120 seconds and tested for API concentration by HPLC. Dissolution curves were plotted and from the first 6 or 7 points on the curves the intrinsic dissolution rate curves were calculated. All tests were carried out at 37° C and a paddle speed of 150 rpm. HPLC-UV Instrument Details

Instrument: Agilent 1200

Column: Gemini C18, 5pm, 150.0 x 4.6mm

Column Temperature: 40°C

Mobile Phase A: Phosphate Buffer

Mobile Phase B: Acetonitrile

Elution: Gradient λ: 210nm

Injection Volume: 10pL

Flow Rate: 1 mL/min

Thin Laver Chromatography (TLC) [0226] A small spot of solution containing the sample was applied to a plate, about one centimeter from the base. The plate is then dipped into the TLC tank (sealed container) containing methanokethyl acetate (95:5) solvent mixture. The solvent moves up the plate by capillary action and meets the sample mixture, which is dissolved and is carried up the plate by the solvent mixture. The number of spots was noted and the Rf values were calculated for each spot.

Infrared (TR)

[0227] Infrared spectroscopy was carried out on a Bruker ALPHA P spectrometer. Sufficient material was placed onto the centre of the plate of the spectrometer and the spectra were obtained using the following parameters: [0228] Resolution: 4 cm-1 [0229] Background Scan Time: 16 scans [0230] Sample Scan Time: 16 scans [0231] Data Collection: 4000 to 400 cm-1 [0232] Result Spectrum: Transmittance [0233] Software: OPUS version 6

Stabilities Studies: pH 1. 4, 7. 10 and 14 Environments [0234] Slurries (supersaturated solution: about 250 μΐ of pH solution and solid was added until dissolution was no longer observed and ca. 100 mg of solid was in the slurry) were prepared for each form in a variety of pH environments; 1, 4, 7, 10 and 13.2.

The slurries were shaken constantly for a period of 14 days and measurements taken at 7 and 14 day time points. Appropriate buffers were prepared for each pH and are detailed further below.

[0235] A buffer having a pH value of 1 was prepared by dissolving 372.75 mg of potassium chloride in 25 ml of deionized water to give a 0.2 M solution. Subsequently, 67 ml of 0.2 M hydrochloric acid was added (this was prepared from a 5 M solution; 10 ml was added to 40 ml of deionized water giving a 1 M solution which was diluted further; 20 ml was added to 80 ml of deionized water giving the required 0.2 M solution) to achieve the desired pH.

[0236] A buffer having a pH value of 4 was prepared by dissolving 1.02 g of potassium hydrogen phthalate in 50 ml of deionized water to give a 0.1 M solution.

[0237] A buffer having a pH value of 7 was prepared by dissolving 680.00 mg of potassium phosphate monobasic in 50 ml of deionized water to give a 0.1 M solution. Subsequently, 29.1 ml of 0.1 M sodium hydroxide was added (this was prepared from a 1 M solution; 5 ml was added to 45 ml of deionized water giving the required 0.1 M solution) to achieve the desired pH.

[0238] A buffer having a pH value of 10 was prepared by dissolving 210.00 mg of sodium bicarbonate in 50 ml of deionized water to give a 0.05 M solution. Subsequently, 10.7 ml of 0.1 M sodium hydroxide was added (this was prepared from a 1 M solution; 5 ml was added to 45 ml of deionized water giving the required 0.1 M solution) to achieve the desired pH.

[0239] A buffer having a pH value of pH 13.2 by dissolving 372.75 mg of potassium chloride in 25 ml of deionized water to give a 0.2 M solution. Subsequently, 66 ml of 0.2 M sodium hydroxide was added (this was prepared from a 1 M solution; 20 ml was added to 80 ml of deionized water giving the required 0.2 M solution) taking the pH to 13. 1M sodium hydroxide was then added drop wise to achieve the desired pH. Example 1: Precipitating Crystalline Forms [0240] Saturated solutions of L-omithine phenyl acetate were subjected to temperature cycling, crash cooling, evaporation, or anti-solvent addition as described above. The precipitate was analyzed by PLM and XRPD to determine the crystalline form (if any). The results are summarized in TABLE 5.

[0241] Six unique crystalline forms were identified from the precipitation studies, Forms I-VI. However, Forms IV and VI were obtained from solutions of acetic acid, and NMR results confirmed these forms to be L-ornithine acetate. Meanwhile, Tests 540-611 utilized samples of L-omithine phenyl acetate originally isolated by the addition of ethanol anti-solvent. Many of these example produced Form I, which is an ethanol solvate, and therefore it is believed these samples originally included residual ethanol. Consequently, Form I may not be reproduced for certain conditions if the original sample does not include residual ethanol. TABLE 5 - Examples of Preparing Crystalline Forms

Example 2: Intrinsic Dissolution Studies [0242] The intrinsic dissolution rates for Forms I, II, and III were measured at pH conditions of 1.0, 4.5 and 6.7. The results are reproduced below in TABLE 6. In each case, complete dissolution was achieved in less than 3 minutes. Surprisingly, a pH dependence was observed for Form II; with the intrinsic dissolution rate increasing with the pH. In contrast, Forms I and III appear to dissolve at rates independent of pH. TABLE 6 - Calculated Intrinsic Dissolution Rates (mg/cmVs)

Example 3: Solubility Studies [0243] The solubility of L-omithine phenyl acetate was approximated according to methods disclosed above. 24 solvents systems were tested: 1,4 dioxane, 1-butanol, ethanol, acetone, benzonitrile, cyclohexane, DCM, DMSO, EtOAc, Heptane, IPA, IPA (1% H20), MeCN, MeCn (1% H20), MEK, MeOAc, methanol, MIBK, Nitromethane, THF, THF (1% H20), Toluene and water. L-ornithine phenyl acetate exhibited a solubility in water, whereas L-omithine phenyl acetate was substantially insoluble in the remaining solvent systems.

[0244] Slurries of L-omithine phenyl acetate in water were also prepared and the slurry was filtered. The filtrate concentration was analyzed by HPLC, and the results show the solubility of L-omithine phenyl acetate to be about 1.072 mg/mL.

[0245] HPLC determinations of solubility were also completed for five solvents: ethanol, acetone, methanol, DMSO and IPA. These results are summarized in TABLE 7. TABLE 7 - HPLC Solubility Determinations [0246] These results indicate that

both acetone and IPA are suitable as antisolvents for precipitating L-omithine phenyl acetate. In contrast, solvents with measurable solubility are less favorable for precipitating crystalline forms of L-ornithine phenyl acetate.

[0247] Finally, the solubility of L-omithine phenyl acetate was determined in various mixtures of IPA and water using HPLC. The results are shown in TABLE 8. TABLE 8 - HPLC Solubility Determinations (IPA/Water)

Example 4: Small-scale Batch Process to Produce L-Omithine Phenyl Acetate [0248] About 8.4g (0.049moles) of L-omithine HC1 was dissolved in 42 mL H2O and, separately, about 11.4g of silver benzoate was dissolved in 57mL DMSO. Subsequently, the silver benzoate solution was added to the L-ornithine HC1 solution. Combining the two mixtures resulted in an immediate, exothermic precipitation of a creamy white solid (AgCl). The solid was removed by vacuum filtration and retaining the filtrate (L-omithine benzoate in solution). 200mL of IP A was added to the filtrate and the mixture was cooled to 4°C. A crystalline solid precipitated after about 3 hours (L-omithine benzoate) which was isolated by vacuum filtration. Yield: 60 % [0249] 7.6 g (0.03moles) of the L-omithine benzoate was dissolved in 38 mL H20 and about 4.4g of sodium phenyl acetate was dissolved 22 mL H20. Subsequently, the sodium phenyl acetate solution was added to the L-ornithine benzoate solution and left to stir for about 10 minutes About 240mL of EPA (8:2 IPA:H20) was added and the solution stirred for 30 minutes before cooling to 4°C. A crystalline solid precipitated after about 3 hrs at 4°C (L-omithine phenyl acetate). The precipitate was isolated by vacuum filtration and washed with 48-144mL of IPA. Yield: 57 %

Example 5: Large-scale Batch Process to Produce L-Ornithine Phenyl Acetate [0250] Two separate batch of L-omithine phenyl acetate were prepared as follows: [0251] About 75 Kg of L-Omithine monohydrochloride was dissolved in 227 kg of water. To the resulting solution was added 102 Kg of silver benzoate dissolved in 266 kg of DMSO at room temperature within 2 hours. Initially, a strong exothermy was observed and the silver chloride precipitated. The receiver containing the solution was then washed with 14 Kg of DMSO that was added to the reaction mass. In order to remove the silver chloride formed, the reaction mass was filtered over a lens filter prepared with 10 kg of Celite and a GAF filter of 1mm. After filtration, the filter was washed with an additional 75 kg of water. The reaction mass was then heated at 35±2° C and 80 kg of sodium phenyl acetate was added. At this point the reaction mass was stirred at 35 ±2° C for at least 30 minutes.

[0252] In order to precipitate the final API, 353 kg of isopropyl alcohol was added to the reaction mass. The reaction mass was then cooled to 0±3°C within 6 hours, stirred for 1 hour and then the product isolated in a centrifuge.

[0253] About 86 kg of finished wet produce was obtained. The product was then dried at 40±5°C for about 6.5 to 8 hours to provide about 75 kg of L-ornithine phenyl acetate. Yield: 63.25. TABLE 9 summarizes measurements relating to the final product. TABLE 9 - Analytical Results for Large-scale Batch Process

Example 6: Reducing Silver Content in L-Omithine Phenyl Acetate [0254] Batch 2 from Example 5 exhibited high amounts of silver (157 ppm), and therefore procedures were tested for reducing the silver content. Nine trials were completed; each generally including dissolving about 20 g of L-omithine phenyl acetate from Batch 2 into 1.9 parts water, and then subsequently adding 10.8 parts IPA. A crystalline form was isolated at 0° C by filtration.

[0255] For four trials, 8.0 mg or 80 mg of heavy metal scavengers SMOPEX 102 or SMOPEX 112 were added to the aqueous solution and stirred for 2 hours. The scavengers failed to reduce the silver content below 126 ppm. Meanwhile, another trial applied the general conditions disclosed above and reduced the silver content to 179 ppm. In still another trial, the L-omithine phenyl acetate was slurried in a solution of IPA, rather than crystallized; however this trial also failed to reduce the silver content below 144 ppm.

[0256] The last three trials included adding diluted HC1 to the solution to precipitate remaining amount of silver as AgCl. The precipitate was then removed by filtration before The three trials included adding: (1) 1.0 g of 0.33% HC1 at 20° C; (2) 1.0 g of 0.33% HC1 at 30° C; and (3) 0.1 g of 3.3% HC1 at 20° C. The three trials reduced the silver content to 30 ppm, 42 ppm, and 33 ppm, respectively, and each trial yielding greater than 90% L-omithine phenyl acetate. Accordingly, the addition of HC1 was effective in reducing the amount of residual silver.

Example 6: Process for Preparing L-Ornithine Phenyl Acetate without an Intermediate Salt [0257] As a general procedure, L-ornithine hydrochloride was suspended in a solvent. After that the reaction mass was heated and a base, sodium methoxide, was added. NaCl formed and was removed from the system by filtration. The reaction mass was cooled and a molar equivalent of phenyl acetic acid was added to the reaction mass in order to form L-ornithine phenyl acetate. The final product was isolated, washed and dried. A summary of the trial for this process is provided in TABLE 10. TABLE 10 - Process Trials

[0258] The resulting L-omithine phenyl acetate was found to exhibit high amounts of chloride (at least about 1% by weight), and presumably include similar amounts of sodium. The yields were about 50% for Trials 2, 4, and 5.

Example 7: Thermal Stability Studies of Forms L II. and III

[0259] Samples of Forms I, II and III were stored at increased temperatures and designated conditions as outlined in TABLE 11. The vacuum applied 600 psi to achieve the reduced pressure. The final compositions were tested by XRPD, NMR, IR and HPLC to determine any changes to the material.

[0260] Most notably, Form III does not transition to Form II under vacuum at 120° C, but rather exhibits greater chemical degradation compared to Forms I and II under these conditions. Meanwhile, Form III converts to Form II and exhibits substantial chemical degradation at 120° C without a vacuum.

[0261] Form I converted to Form II in all the trials, but most interestingly, Form I exhibits substantial chemical degradation at 120° C without a vacuum. Thus, the conversion from Form I does not exhibit the same chemical stability as Form II, which is surprising considering the material readily converts to Form II.

[0262] Form II was stable and did not chemically degrade in all of the trials. Thus, Form II is the most stable. Meanwhile, Form III is more stable than Form I, but both forms exhibit substantial chemical degradation at 120° C without a vacuum. TABLE 11 - Thermal Stability Trials

[0263] HPLC results for the trials exhibiting chemical degradation (e.g., Trial 10 from TABLE 11) are summarized in TABLE 12. Each degraded material exhibits common peaks at relative retention times (RRT) of 1.9, 2.2, 2.4, and 2.7, which suggests a common degradation pathway for different forms. TABLE 12 - HPLC Results for Degraded Samples

Example 8: Oxygen Stability Studies of Forms I. II, and III

[0264] Samples of Forms I, II and III were stored in 100% oxygen environments for 7 or 14 days and analyzed by NMR and IR. The results establish that Forms I and II show no signs of degradation after 14 days. Only IR results were completed for Form III at 7 days, and these results confirm there was no significant degradation. TLC results for all samples indicated a single spot with similar Rf values. Example 9: UV Stability Studies of Forms I. II. and III

[0265] Samples of Forms I, II and III were exposed to ultraviolet (UV) radiation for 7 or 14 days. A CAMAG universal UV Lampe applied radiation to the samples with setting of 254 mp. NMR and IR results show no degradation of Forms I and

11 after 14 days. Similarly, Form III exhibits no degradation after 7 days as determined by NMR and IR. TLC results for all samples indicated a single spot with similar Rf values. Example 10: pH Stability Studies of Forms I. II. and III

[0266] A slurry of Forms I, II and III were formed with water and the pH value adjusted to either 1.0, 4.0, 7.0, 10.0, and 13.2. The slurries were stored for 7 or 14 days, and subsequently the solids were removed by filtration. Form I converted to Form II in all of the samples. NMR and IR results show Forms I and II did not degrade after 14 days in the varied pHs, and similarly HPLC results show about 98% purity or more for these samples. Form III also exhibited no degradation after 7 days according to NMR and IR results. HPLC tests show about 95% purity or more; however IR results show Form III converted to Form II over the 7-day test. TLC results for all samples indicated a single spot with similar Rf values.

Example 11: Compression Studies of Forms I. II. and III

[0267] Samples of Forms I, II and III were subjected to 3 tons of force using a Moore Hydraulic Press for about 90 minutes. The resultant tablet’s mass, diameter and thickness were measured to determine the density. The tablets were also analyzed by NMR and IR. Form I transitioned to a composition of Form II with a density of 1.197 kg/m3. Form II did not exhibit a transition and had a final density of 1.001 kg/m3. Finally, Form III did not exhibit a transition and had a final density of 1.078 kg/m3. Example 12: Process for Producing L-Omithine Phenyl Acetate via an Acetate Intermediate [0268] Dissolve 25 mg of L-ornithine HC1 5 vols of H2O, and then add excess acetic acid (about 5 vols) to form a slurry. Subject the slurry to temperature cycling between 25° and 40° C every 4 hours for about 3 days. Add 1 equivalent of phenylacetic acid (with respect to L-ornithine) and stir for about 4-6 hrs (possibly heat). Use IPA as an anti-solvent, add enough to obtain a ratio of 70:30 (ΙΡΑ:Η2θ). Isolate by vacuum filtration and dry for about 4-8 hrs at 80 °C to remove any residual acetic acid.

Claims (118)

1. WHAT IS CLAIMED IS:

   1. A composition comprising a crystalline form of L-omithine phenyl acetate.
2. 2. The composition of Claim 1, wherein said crystalline form exhibits an X-ray powder diffraction pattern comprising at least one characteristic peak, wherein said characteristic peak is selected from the group consisting of approximately 6.0°, 13.9°, 14.8°, 17.1°, 17.8° and 24.1° 2Θ.
3. 3. The composition of Claim 2, wherein said crystalline form exhibits an X-ray powder diffraction pattern comprising at least three characteristic peaks, wherein said characteristic peaks are selected from the group consisting of approximately 6.0°, 13.9°, 14.8°, 17.1°, 17.8° and 24.1° 2Θ.
4. 4. The composition of any one of Claims 2-3, wherein said crystalline form exhibits an X-ray powder diffraction pattern comprising characteristic peaks at approximately 6.0°, 13.9°, 14.8°, 17.1°, 17.8° and 24.1° 20.
5. 5. The composition of any one of Claims 1-4, wherein said crystalline form has a melting point of about 202° C.
6. 6. The composition of any one of Claims 1-5, wherein said crystalline form exhibits a single crystal X-ray crystallographic analysis with crystal parameters approximately equal to the following: unit cell dimensions: a=6.594(2) A, b=6.5448(18) A, ¢=31.632(8) A, α=90°,β=91.12(3)°, γ=90°; Crystal System: Monoclinic; and Space Group: P2].
7. 7. The composition of any one of Claims 1-6, wherein the said crystalline form is represented by the formula [C5H13N2O2HC8H7O2].
8. 8. The composition of Claim 1, wherein said crystalline form exhibits an X-ray powder diffraction pattern comprising at least one characteristic peak, wherein said characteristic peak is selected from the group consisting of approximately 4.9°, 13.2°, 17.4°, 20.8° and 24.4° 20.
9. 9. The composition of Claim 8, wherein said crystalline form exhibits an X-ray powder diffraction pattern comprising at least three characteristic peaks, wherein said characteristic peaks are selected from the group consisting of approximately 4.9°, 13.2°, 17.4°, 20.8° and 24.4° 20.
10. 10. The composition of any one of Claims 8-9, wherein said crystalline form exhibits an X-ray powder diffraction pattern comprising characteristic peaks at approximately 4.9°, 13.2°, 17.4°, 20.8° and 24.4° 2Θ.
11. 11. The composition of any one of Claims 1 and 8-10, wherein said crystalline form comprises water and/or ethanol molecules.
12. 12. The composition of Claim 11, wherein said crystalline form comprises about 11% by weight of said molecules as determined by thermogravimetric analysis.
13. 13. The composition of any one of Claims 1 and 8-12, wherein said crystalline form is characterized by differential scanning calorimetry as comprising an endotherm at about 35° C.
14. 14. The composition of Claim 13, further comprising a melting point at about 203° C.
15. 15. The composition of any one of Claims 1 and 8-14, wherein said crystalline form exhibits a single crystal X-ray crystallographic analysis with crystal parameters approximately equal to the following: unit cell dimensions: a=5.3652(4) A, b=7.7136(6) A, c=20.9602(18) A, α=90°, β=94.986(6)°, γ=90°; Crystal System: Monoclinic; and Space Group: P2i.
16. 16. The composition of any one of Claims 1 and 8-15, wherein the said crystalline form is represented by the formula [C5Hi3N202][CgH702]Et0H.H20.
17. 17. The composition of Claim 1, wherein said crystalline form exhibits an X-ray powder diffraction pattern comprising at least one characteristic peak, wherein said characteristic peak is selected from the group consisting of approximately 5.8°, 14.1°, 18.6°, 19.4°, 22.3° and 24.8° 2Θ.
18. 18. The composition of Claim 17, wherein said crystalline form exhibits an X-ray powder diffraction pattern comprising at least three characteristic peaks, wherein said characteristic peaks are selected from the group consisting of approximately 5.8°, 14.1°, 18.6°, 19.4°, 22.3° and 24.8° 2Θ.
19. 19. The composition of any one of Claims 17-18, wherein said crystalline form exhibits an X-ray powder diffraction pattern comprising characteristic peaks at approximately 5.8°, 14.1°, 18.6°, 19.4°, 22.3° and 24.8° 2Θ.
20. 20. The composition of any one of Claims 1 and 17-19, wherein said crystalline form is characterized by differential scanning calorimetry as comprising an endotherm at about 40° C.
21. 21. The composition of Claim 20, further comprising a melting point at about 203° C.
22. 22. The composition of Claim 1, wherein said crystalline form exhibits an X-ray powder diffraction pattern comprising at least one characteristic peak, wherein said characteristic peak is selected from the group consisting of approximately 13.7°, 17.4°, 19.8°, 20.6° and 23.7° 20.
23. 23. The composition of Claim 22, wherein said crystalline form exhibits an X-ray powder diffraction pattern comprising at least three characteristic peaks, wherein said characteristic peak is selected from the group consisting of approximately 13.7°, 17.4°, 19.8°, 20.6° and 23.7° 20.
24. 24. The composition of Claim 23, wherein said crystalline form exhibits an X-ray powder diffraction pattern comprising characteristic peaks at approximately 13.7°, 17.4°, 19.8°, 20.6° and 23.7° 20.
25. 25. The composition of any one of Claims 1 and 22-24, wherein said crystalline form is characterized by differential scanning calorimetry as comprising an endotherm at about 174°C.
26. 26. The composition of Claim 25, wherein said crystalline form has a melting point of about 196° C.
27. 27. The composition of any one of Claims 1-26, further comprising a pharmaceutically acceptable carrier.
28. 28. A composition comprising: at least about 50% by weight of a crystalline form of L-ornithine phenyl acetate salt; and at least about 0.01% by weight benzoic acid or a salt thereof.
29. 29. The composition of Claim 28, wherein the composition comprises at least about 0.10% by weight benzoic acid or a salt thereof.
30. 30. The composition of any one of Claims 28-29, wherein the composition comprises no more than 5% by weight benzoic acid or a salt thereof.
31. 31. The composition of any one of Claims 28-29, wherein the composition comprises no more than 1% by weight benzoic acid or a salt thereof.
32. 32. The composition of any one of Claims 28-31, wherein the composition further comprises at least 10 ppm silver.
33. 33. The composition of any one of Claims 28-31, wherein the composition further comprises at least 20 ppm silver.
34. 34. The composition of any one of Claims 28-31, wherein the composition further comprises at least 25 ppm silver.
35. 35. The composition of any one of Claims 28-31, wherein the composition comprises no more than 600 ppm silver.
36. 36. The composition of any one of Claims 32-34, wherein the composition comprises no more than 100 ppm silver.
37. 37. The composition of any one of Claims 32-34, wherein the composition comprises no more than 65 ppm silver.
38. 38. The composition of any one of Claims 32-37, wherein about 50 mg/mL of said composition in water is isotonic with body fluids.
39. 39. The composition of Claim 38, wherein the isotonic solution has an osmolality in the range of about 280 to about 330 mOsm/kg.
40. 40. The composition of any one of Claims 32-39, wherein the composition has a density in the range of about 1.1 to about 1.3 kg/m3.
41. 41. A process for making L-ornithine phenyl acetate salt comprising: intermixing an L-ornithine salt, a benzoate salt and a solvent to form an intermediate solution; intermixing phenyl acetate with said intermediate solution; and isolating a composition comprising at least 70% crystalline L-ornithine phenyl acetate by weight.
42. 42. The process of Claim 41, further comprising removing at least a portion of a salt from said intermediate solution before intermixing the phenyl acetate, wherein said salt is not an L-omithine salt.
43. 43. The process of Claim 42, wherein the process further comprises adding hydrochloric acid before removing at least a portion of the salt.
44. 44. The process of any one of Claims 41-42, wherein intermixing the L-ornithine, the benzoate salt and the solvent comprises: dispersing the L-ornithine salt in water to form a first solution; dispersing the benzoate salt in DMSO to form a second solution; and intermixing said first solution and said second solution to form said solution.
45. 45. The process of any one of Claims 41-44, wherein said composition comprises at least about 0.10% by weight benzoate salt.
46. 46. The process of Claim 45, wherein said composition comprises no more than 5% by weight benzoate salt.
47. 47. The process of Claim 46, wherein said composition comprises no more than 1 % by weight benzoate salt.
48. 48. The process of any one of Claims 41-47, wherein the L-ornithine salt is L-ornithine hydrochloride.
49. 49. The process of any one of Claims 41-48, wherein the benzoate salt is silver benzoate.
50. 50. The process of Claim 49, wherein said composition further comprises at least 10 ppm silver.
51. 51. The process of Claim 50, wherein said composition comprises at least 20 ppm silver.
52. 52. The process of Claim 51, wherein said composition comprises at least 25 ppm silver.
53. 53. The process of any one of Claims 49-52, wherein said composition comprises no more than 600 ppm silver.
54. 54. The process of Claim 53, wherein said composition comprises no more than 100 ppm silver.
55. 55. The process of Claim 54, wherein the composition comprises no more than 65 ppm silver.
56. 56. The process of any one of Claims 41-55, wherein the phenyl acetate is in an alkali metal salt.
57. 57. The process of Claim 56, wherein the alkali metal salt is sodium phenyl acetate.
58. 58. The process of Claim 57, wherein said composition comprises no more than 100 ppm sodium.
59. 59. The process of Claim 58, wherein said composition comprises no more than 20 ppm sodium.
60. 60. The process of any one of Claims 41-59, wherein the L-omithine is in a halide salt.
61. 61. The process of Claim 60, wherein the halide salt is L-ornithine hydrochloride.
62. 62. The process of Claim 61, wherein the composition comprises no more than 0.1% by weight chloride.
63. 63. The process of Claim 62, wherein the composition comprises no more than 0.01% by weight chloride.
64. 64. The composition obtained by the process of any one of Claims 41-63.
65. 65. A process for making L-omithine phenyl acetate salt comprising: increasing the pH value of a solution comprising an L-ornithine salt at least until an intermediate salt precipitates, wherein said intermediate salt is not an L-omithine salt; isolating the intermediate salt from said solution; intermixing phenyl acetic acid with said solution; and isolating L-omithine phenyl acetate salt from said solution.
66. 66. The process of Claim 65, wherein the pH value is increased to at least 8.0.
67. 67. The process of Claim 66, wherein the pH value is increased to at least 9.0.
68. 68. The process of any one of Claims 65-67, wherein increasing the pH value comprises adding a pH modifier selected from the group consisting of sodium hydroxide, potassium hydroxide, sodium methoxide, potassium t-butoxide, sodium carbonate, calcium carbonate, dibutylamine, tryptamine, sodium hydride, calcium hydride, butyllithium, ethylmagnesium bromide or combinations thereof.
69. 69. A method of treating or ameliorating hyperammonemia in a subject by administering a therapeutically effective amount of a crystalline form of L-ornithine phenyl acetate salt.
70. 70. The method of Claim 69, wherein said crystalline form is administered orally.
71. 71. The method of any one of Claims 69 and 70, wherein said crystalline form is selected from the group consisting of Form I, Form II, Form III, Form V, wherein: said Form I exhibits an X-ray powder diffraction pattern having characteristic peaks at approximately 4.9°, 13.2°, 17.4°, 20.8° and 24.4° 20; said Form II exhibits an X-ray powder diffraction pattern having characteristic peaks at approximately 6.0°, 13.9°, 14.8°, 17.1°, 17.8° and 24.1° 20; said Form III exhibits an X-ray powder diffraction pattern having characteristic peaks at approximately 5.8°, 14.1°, 18.6°, 19.4°, 22.3° and 24.8° 2Θ; and said Form V exhibits an X-ray powder diffraction pattern having characteristic peaks at approximately 13.7°, 17.4°, 19.8°, 20.6° and 23.7° 2Θ.
72. 72. The method of Claims 71, wherein said crystalline form is Form I.
73. 73. The method of Claims 71, wherein said crystalline form is Form II.
74. 74. The method of Claims 71, wherein said crystalline form is Form III.
75. 75. The method of Claims 71, wherein said crystalline form is Form V.
76. 76. The method of Claims 71, wherein at least two crystalline forms selected from the group consisting of Form I, Form II, Form III and Form V, are administered.
77. 77. The method of Claim 76, wherein said at least two crystalline forms are administered at about the same time.
78. 78. The method of any one of Claims 71-77, wherein said crystalline form is administered from 1 to 3 times daily.
79. 79. The method of any one of Claims 71-78, wherein said therapeutically effective amount is in the range of about 500 mg to about 50 g.
80. 80. The method of any one of Claims 71-79, wherein the subject is identified as having hepatic encephalopathy.
81. 81. The method of any one of Claims 71-79, wherein the subject is identified as having hyperammonemia.
82. 82. A process for making L-omithine phenyl acetate salt comprising: intermixing an L-ornithine salt, silver phenyl acetate and a solvent to form a solution, wherein the L-ornithine salt is an alkali metal salt; and isolating L-omithine phenyl acetate from said solution.
83. 83. A method of treating or ameliorating hyperammonemia comprising intravenously administering a therapeutically effective amount of a solution comprising L-omithine phenyl acetate, wherein said therapeutically effective amount comprises no more than 500 mL of said solution.
84. 84. The method of Claim 83, wherein the solution comprises at least about 25 mg/mL of L-ornithine phenyl acetate.
85. 85. The method of any one of Claims 83-84, wherein the solution comprises at least about 40 mg/mL of L-ornithine phenyl acetate.
86. 86. The method of any one of Claims 83-85, wherein the solution comprises no more than 300 mg/mL.
87. 87. The method of any one of Claims 83-86, wherein the solution is isotonic with body fluid,
88. 88. A method of compressing L-ornithine phenyl acetate, the method comprising applying pressure to a metastable form of L-ornithine phenyl acetate to induce a phase change.
89. 89. The method of Claim 88, wherein the metastable form is amorphous.
90. 90. The method of Claim 88, wherein the metastable form exhibits an X-ray powder diffraction pattern comprising at least one characteristic peak, wherein said characteristic peak is selected from the group consisting of approximately 4.9°, 17.4, 13.2°, 20.8° and 24.4° 2Θ.
91. 91. The method of any one of Claims 88-90. wherein the pressure is applied for a predetermined time.
92. 92. The method of Claim 91, wherein the predetermined time is about 1 second or less.
93. 93. The method of any one of Claims 88-92, wherein the pressure is at least about 500 psi.
94. 94. The method of any one of Claims 88-93, wherein the phase change yields a composition having a density in the range of about 1.1 to about 1.3 kg/nr after applying the pressure.
95. 95. The method of any one of Claims 88-94, wherein the phase change yields a composition exhibiting an X-ray powder diffraction pattern comprising at least one characteristic peak, wherein said characteristic peak is selected from the group consisting of approximately 6.0°, 13.9°, 14.8°, 17.Γ, 17.8° and 24.1° 2Θ.
96. 96. A composition prepared according to the method of any one of Claims 88-95.
97. 97. A process for making L-ornithine phenylacetate comprising: intermixing an L-omithine salt, a benzoate salt and a solvent to form an intermediate solution; intermixing phenylacetate with said intermediate solution; and isolating a composition comprising at least 70% crystalline L-ornithine phenylacetate by weight.
98. 98. The process of Claim 97, further comprising removing at least a portion of a salt from said intermediate solution before intermixing the phenylacetate, wherein said salt is not an L-ornithine salt.
99. 99. The process of Claim 98, wherein the process further comprises adding hydrochloric acid before removing at least a portion of the salt.
100. 100. The process of Claim 97 or Claim 98, wherein intermixing the L-ornithine, the benzoate salt and the solvent comprises: dispersing the L-omithine salt in water to form a first solution; dispersing the benzoate salt in DMSO to form a second solution; and intermixing said first solution and said second solution to form said intermediate solution.
101. 101. The process of any one of Claims 97-100, wherein said composition comprises at least about 0.10% by weight benzoate salt.
102. 102. The process of Claim 101, wherein said composition comprises no more than 5% by weight benzoate salt.
103. 103. The process of Claim 102, wherein said composition comprises no more than 1% by weight benzoate salt.
104. 104. The process of any one of Claims 97-103, wherein the benzoate salt is silver benzoate.
105. 105. The process of Claim 104, wherein said composition further comprises at least 10 ppm silver.
106. 106. The process of Claim 105, wherein said composition comprises at least 20 ppm silver.
107. 107. The process of Claim 106, wherein said composition comprises at least 25 ppm silver.
108. 108. The process of any one of Claims 104-107, wherein said composition comprises no more than 600 ppm silver.
109. 109. The process of Claim 108, wherein said composition comprises no more than 100 ppm silver.
110. 110. The process of Claim 109, wherein the composition comprises no more than 65 ppm silver.
111. 111. The process of any one of Claims 97-110, wherein the phenylacetate is in an alkali metal salt.
112. 112. The process of Claim 111, wherein the alkali metal salt is sodium phenylacetate.
113. 113. The process of Claim 112, wherein said composition comprises no more than 100 ppm sodium.
114. 114. The process of Claim 113, wherein said composition comprises no more than 20 ppm sodium.
115. 115. The process of any one of Claims 97-117, wherein the L-ornithine is in a halide salt.
116. 116. The process of Claim 115, wherein the halide salt is L-ornithine hydrochloride.
117. 117. The process of Claim 116, wherein the composition comprises no more than 0.1% by weight chloride.
118. 118. The process of Claim 117, wherein the composition comprises no more than 0.01% by weight chloride.